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Abstract
 In Africa, the clinical syndrome of pneumonia remains theBackground:
leading cause of morbidity and mortality in children in the post-neonatal period.
This represents a significant burden on in-patient services. The targeted use of
oxygen and simple, non-invasive methods of respiratory support may be a
highly cost-effective means of improving outcome, but the optimal oxygen
saturation threshold that results in benefit and the best strategy for delivery are
yet to be tested in adequately powered randomised controlled trials. There is,
however, an accumulating literature about the harms of oxygen therapy across
a range of acute and emergency situations that have stimulated a number of
trials investigating permissive hypoxia.
 In 4200 African children, aged 2 months to 12 years, presenting to 5Methods:
hospitals in East Africa with respiratory distress and hypoxia (oxygen saturation
< 92%), the COAST trial will simultaneously evaluate two related interventions
(targeted use of oxygen with respect to the optimal oxygen saturation threshold
for treatment and mode of delivery) to reduce shorter-term mortality at 48-hours
(primary endpoint), and longer-term morbidity and mortality to 28 days in a
fractional factorial design, that compares:
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 Discuss this article
 (0)Comments
1.  
2.  
Liberal oxygenation (recommended care) compared with a strategy that
permits hypoxia to SpO > or = 80% (permissive hypoxia); and
High flow using AIrVO  compared with low flow delivery (routine
care).
The overarching objective is to address the key research gaps inDiscussion: 
the therapeutic use of oxygen in resource-limited setting in order to provide a
better evidence base for future management guidelines. The trial has been
designed to address the poor outcomes of children in sub-Saharan Africa,
which are associated with high rates of in-hospital mortality, 9-10% (for those
with oxygen saturations of 80-92%) and 26-30% case fatality for those with
oxygen saturations <80%.
Clinical trial registration: ISRCTN15622505
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1. Introduction
Worldwide, the clinical syndrome of pneumonia remains the 
leading cause of death in children in the post-neonatal period and 
therefore presents a significant burden on health services1,2. The 
greatest burden of the mortality is in South East Asia and sub- 
Saharan Africa where over 70% of these deaths occur annually3. 
The World Health Organization (WHO) recommends presumptive 
antibiotic treatment based on clinical syndromic definitions of 
pneumonia plus oxygen for those with clinically very severe 
pneumonia (VSP) or when available to those with hypoxaemia – 
defined as oxygen saturation (SpO2) <90% measured by a pulse 
oximeter4. Nevertheless, there is substantial evidence that current 
syndromic management guidelines are not working in practice, 
resulting in high in-hospital mortality (9–16%)5,6. Furthermore, 
severe pneumonia contributes to a ‘hidden burden’ of childhood 
mortality in the months following hospital admission, with those 
who survive severe pneumonia having a 2.5-fold increased risk 
of mortality post-hospital discharge compared to children admit-
ted without severe pneumonia7. The key risk factor for poor out-
come has been identified as undernutrition8. For those admitted 
to hospital, hypoxaemia (SpO2 <90%) is present on admission in 
9.4% and 13.3% of children hospitalised with severe pneumonia 
(SP) and VSP, respectively, and is an important indicator of dis-
ease severity9. The targeted use of oxygen and simple, non-invasive 
methods of respiratory support may be a highly cost-effective 
means of improving outcome, but both the optimal oxygen satu-
ration threshold that results in benefit and the best strategy for 
delivery are yet to be tested in adequately powered randomised 
controlled trials (RCT). Oxygen as a potentially life-saving 
treatment, though advocated by the WHO technologies group, 
yet it has not been afforded a high enough priority in Africa or 
globally10,11. For example, in order to assess the health services 
‘preparedness’ for pandemic influenza, 231 health facilities 
were surveyed across 12 African countries. They found that only 
44% reported having uninterrupted oxygen supplies, with 24% 
possessing a functioning oxygen concentrator (the WHO pre-
ferred method for oxygen delivery) and reliable electricity power 
supplies were reported in 35%11.
Systematic and policy reviews indicate the need for a formal 
evaluation of the hypoxaemia threshold at which oxygen should be 
targeted and of how oxygen is best administered9,12,13. The COAST 
trial aims to address these key research gaps to provide a better 
evidence base for future guidelines, with a view to improving 
poor outcomes.
1.1 Clinical burden of pneumonia
The clinical syndrome of pneumonia remains the leading cause 
of childhood death in sub-Saharan Africa1, despite public health 
interventions including immunization. Substantial investment 
in international multi-country research and vaccine implemen-
tation will undoubtedly reduce the burden of disease and lead 
to refinements of current guidelines. The current WHO clinical 
criteria for identification of pneumonia aim at prioritising sensi-
tivity over specificity. Thus, emerging results from prospective 
studies of hospitalised children with WHO criteria for pneu-
monia indicate that it encompasses a much broader range of 
aetiologies, particularly in sub-Saharan Africa, than those likely 
to be averted by current and planned public health measures, such 
as immunisation programmes or early identification and pre- 
hospital antimicrobial treatment5,14. Adverse outcomes are not 
uncommon, despite early diagnosis and treatment5,14,15. As the 
clinical syndrome of pneumonia is very common amongst hos-
pitalised children, the high early mortality remains a significant 
barrier to improving survival statistics14–16, important for attain-
ment of Sustainable Developmental Goals’ targets on health.
1.2 Hypoxaemia in ‘pneumonia’ syndromes
A systematic review examining the prevalence of hypoxaemia, 
including 24 published and unpublished data sets from Africa, 
Asia/Oceania and Latin America, reported a median preva-
lence of hypoxaemia for SP was 9.4% (interquartile range (IQR) 
7.5–18.5%) and 13.3% (IQR 9.3–37.5%) for those with VSP9. 
Mortality rates were not reported. Conservative estimates, based 
on these data, indicated that the annual worldwide burden of 
hypoxaemia in hospitalised pneumonia alone was between 1.5 and 
2.7 million cases.
In an unselected paediatric (excluding neonates) admission 
population of 13,183 Kenyan children admitted to Kilifi District 
Hospital and where all admissions had a standard admission 
proforma, including pulse oximetry, if the WHO clinical criteria 
for severe and very severe criteria were applied then this would 
mean that 4792/13,183 or 36% of all admissions would be 
classified as having VSP or SP; when in reality only 2168 
(16%) had a final diagnosis of SP or VSP. Relevant to clinical 
practice (in hospitals where plus oximetry in not available) this 
would mean that if these were applied then 36% of all paediat-
ric cases would fulfil criteria to receive oxygen. Yet in the Kilifi  
District Hospital studies only 291/2525 (11.5%) of children 
classified as VSP and 156/2267 (6.9%) of children classified as SP 
had hypoxaemia (oxygen saturation <90%) (Figure 1)5. Moreover, 
most of the children classified as VSP on admission, clinical 
criteria (2011; 80%) had another final diagnoses rather than pneu-
monia. Most common causes of hypoxaemic were malaria 
(244, 35%), lower respiratory tract infection (LRTI) (221, 
32%), malnutrition (68, 10%) and gastroenteritis (49, 7%). 
Severe anaemia was found in 30 children (<1%).
      Amendments from Version 1
The protocol includes some minor edits that resulted from the 
initial review- these were clarification of hypoxaemia rather than 
hypoxia, the correction of some ‘typos’ . The Trial flow figures 
have been updated to include these (Figure 4 and Figure 6) in 
addition we have replaced in Figure 6 COAST B for STRATUM 2. 
Finally, we have added an additional author Prof John Fraser 
who contributed to the overall study design with regards 
to implementation and operationalisation of the high flow 
oxygenation strategies in the trial. Key research link to Fisher and 
Paykel Health Care, who have donated the AIrVO2 machines and 
consumables to the COAST trial. 
See referee reports
REVISED
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1.3 Adoption of pulse oximetry in clinical practice
English et al. demonstrates that the use of pulse oximetry has 
been very poorly implemented across hospitals in Kenya despite it 
being recommended for triage of sick children17. Between 2002 
and 2009, none of 17 hospitals had a pulse oximeter, by 2012 
only 3 of 22 (14%) of hospitals surveyed had a pulse oximeter. 
As a result, in most hospitals in Kenya, clinicians therefore pre-
scribe oxygen ‘blind’ and since clinical signs poorly predict 
those with true hypoxaemia5 (Figure 1) a large number of chil-
dren without hypoxaemia receive oxygen, which raises questions 
over safety18,19, cost and demand on scare health resources20. In 
addition, in the absence of pulse oximetry, there is an even larger 
burden of children with hypoxaemia that are not identified for 
oxygen therapy.
1.4 Mortality associated with hypoxaemia
The importance of hypoxaemia, as a key predictor of mortality, is 
underlined in prospective studies. In the above study by Mwaniki 
et al., overall 753 (6%) children died, including 150 (22%) of 
those with hypoxaemia. In Indonesia, children aged <2 years 
admitted with SP (overall 12% hospital mortality) demonstrated 
that hypoxic thresholds associated with increased mortality dif-
fered by age21. For children aged <4 months, this was SpO2<88%, 
whereas for children aged >4 months it was <80%. Another 
study conducted in Kenya, found that children with hypoxaemia 
had a 5-fold increase of mortality compared to those without 
hypoxaemia22.
Predicting mortality in sick African children (PET score) was 
developed from the FEAST trial23. The FEAST trial was a con-
trolled trial of fluid bolus therapy, which took place between 
2009 and 2011 in six centres (including large regional referral 
hospitals and small district hospitals-none of which had access 
to mechanical ventilation) in three countries (Kenya, Uganda 
and Tanzania), in East Africa. In these three countries national 
vaccination programmes at the time of the trial included 
Haemophilus influenzae type B (HiB) vaccine, but did not include 
pneumococcal vaccination. Children, aged between 2 months 
and 12 years, with severe febrile illness were included in the trial 
(n= 3170) if they had additional features of severity (impaired 
Figure 1. Lower respiratory tract infections and other non-respiratory diagnoses in 13,183 Kenyan children admitted to hospital (from 
Mwaniki et al. 2009; 5).
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consciousness or respiratory distress children) and clinical evi-
dence of impaired perfusion24, ISCRTN69856593). The pri-
mary outcome was 48-hour mortality. Prior to during the trial the 
clinical trial teams (clinicians and nurses) received Emergency 
Triage Assessment and Treatment (ETAT) training, with rel-
evant guidance to ensure equipoise for the essential question 
the FEAST trial was addressing. Reliable supplies of oxygen 
therapy were only available in two of the six hospitals, and 
thus oxygen concentrators were provided for those lacking such 
equipment.
A secondary analysis of the FEAST trial data developed a clini-
cal bedside risk score (the PET prognostic score) that examined 
clinical and laboratory prognostic factors for mortality using 
multivariable Cox regression to build a model in the no-bolus 
control arm of the FEAST trial. The aim was to develop a score, 
which was also externally validated on two admissions datasets 
from Kilifi District Hospital, Kenya, and compared to other pub-
lished risk scores. The final model included 8 clinical variables 
(temperature, heart rate, capillary refill time, conscious level, severe 
pallor, respiratory distress, lung crepitations and a weak pulse 
volume), but notably did not include hypoxaemia. The strongest 
prognostic factors for mortality were coma, bradycardia (<80 beats 
per min) or severe tachycardia (>220 beats per min). Included 
in the PETAL score were additional laboratory markers lactate, 
urea and pH which added further information to the score. 
Oxygen saturation, although considered important in other 
studies, did not significantly improve the discriminative ability 
of the score in PETAL dataset and therefore not included in the 
final model.
1.5 Aetiology of pneumonia
The admission cohort of Kenyan children, reported above, dem-
onstrated that 80% (n=2011) of children fulfilling VSP criteria 
had a non-pneumonic cause of respiratory distress5. At the same 
centre, this was further explored in a case-control study examining 
pathogenic aetiology of children aged <5 years hospitalised with 
SP, in the era prior to the introduction of pneumococcal vaccine. 
Out of the 984 cases, 810 (84%) were eligible to be enrolled in 
the study. Of these 232 (29%) fulfilled WHO clinical signs of VSP. 
Out of the 749 with blood cultures result, 52 (7%) were positive 
in cases, of which 30/52 (58%) were Streptococcus pneumoniae. 
Bacterial aetiology was established in 23% (SPN=viral in 13%, 
mixed in 2% and 63% were of unknown aetiology)14. There was 
no association found between most causes of viral infection of 
the nasopharynx and pneumonia, except for respiratory syncytial 
virus. No identifiable pathogen was found in any of the deaths. 
In a study conducted in Fijian children with a discharge diagno-
sis of LRTI, only 34% met WHO standardised criteria for chest 
x-ray confirmed pneumonia25. Thus, after the introduction of the 
PCV vaccine, which has now been implemented across all the 
proposed sites for the COAST trial, the proportion of children 
with actual bacterial pneumonia will be substantially lower than 
the estimates approximately by 50%, generated from previous 
studies preceding the era of pneumococcal vaccination role out.
1.6 Current treatment recommendations for pneumonia
The WHO guidelines for management of children in hospital 
in resource-limited settings recommend presumptive antibiotic 
treatment based on clinical syndromes involving a history of cough 
or difficulty breathing with lower chest wall in drawing, or signs 
indicating VSP; it also recommends oxygen for those with VSP 
or hypoxaemia (Table 1)4. The normal range of acceptable SpO2 
values differs according to age and altitude. At sea level, normal 
values are generally considered to be a SpO2 >94%. Thresholds 
for administering oxygen differ among international guidelines 
– some target <92%, whilst others target <94% (reviewed in 
Cunningham26). The lack of evidence that maintaining ‘normal’ 
oxygen values in critically ill patients is beneficial, possibly 
explains the wide variation in practice surrounding the manage-
ment of hypoxaemia. For children in resource-poor countries, the 
WHO recommended threshold for giving oxygen therapy is 
SpO2 <90%, or SpO2 <87% if living at altitude >2500m12. In the 
2013 WHO guidelines, the revision of the definitions of the cat-
egories of pneumonia mean that VSP and SP were collapsed into 
one category (‘Severe pneumonia’) and the definition included 
Table 1. World Health Organization (WHO) guidelines recommended treatment for pneumonia.
Type Where to 
treat
Oxygen
WHO 2005 recommendations3
Very severe 
pneumonia Inpatient
      •  Give to all children with very severe pneumonia if pulse oximetry 
available, give to children with oxygen saturation <90%
      • Use nasal prongs (NP), nasal catheter, or nasopharyngeal catheter
Severe pneumonia Inpatient       •  If readily available, give to any child with severe lower chest wall in drawing or a respiratory rate of >70/minute
Pneumonia Outpatient       • Not required
WHO 2013 recommendations27
Severe pneumonia Inpatient
      • Give if oxygen saturation <90%
      •  Use NPs as the preferred method of oxygen delivery to young 
infants
Pneumonia Outpatient       • Not required
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children with a history of cough and one or more of signs of puta-
tive pneumonia, including with respiratory distress, evidence of 
hypoxaemia (central cyanosis or oxygen saturations of <90%) or 
danger signs (lethargy or greater, convulsions). Oxygen is rec-
ommended for those with oxygen saturations of <90%, yet most 
hospitals in developing countries lack the facility to measure this17.
1.7 Availability of therapeutic oxygen: Technical and 
clinical challenges
There is substantial evidence that even after substantial invest-
ment for influenza epidemic preparedness, there are significant 
gaps between supply and demand for oxygen in most hospitals 
in developing countries11. Technical reports on the operational 
quality, availability and reliability of cylinders or oxygen concen-
trators indicate that, even when available, these are often faulty 
(substantial leakage from cylinders and lack of maintenance 
for both) and/or unsustainable due to high cost, erratic supply 
chain due to logistics and technical challenges (termed the ‘oxy-
gen supply chain’)28 or dependence upon unreliable electricity 
supply11,29–31. However, in practice, this results in severe shortages 
of oxygen and intermittent supply of oxygen (where electrical 
power supplies permit).
Few hospitals have access to pulse oximeters32 and the sustain-
able provision of bottled oxygen or oxygen concentrators are both 
expensive and logistically challenging33. As a consequence of this 
and the high, often seasonal, burden of children fulfilling severe 
and very severe pneumonia definitions33, many children who fulfil 
the current criteria for oxygen do not receive it (standard ‘usual 
care’). Instead, the current reliance on non-specific clinical signs 
to guide oxygen therapy results in the poorly targeted use of a 
costly intervention5 – as a result few children who may benefit from 
oxygen therapy actually receive it.
The 2012 WHO Recommendations for management of common 
childhood conditions identified a number of key research questions 
as ‘Research Gaps’, which included: large-scale effectiveness 
trials of improved oxygen systems on outcomes from pneumonia; 
and clinical studies comparing outcomes when oxygen is given at 
different thresholds12.
1.8 Evidence from clinical trials and systematic reviews
Both inadequate tissue oxygenation and excessive oxygen 
administration (causing hyperoxaemia) are likely to be detrimental 
to outcome. These are two considerations that should inform 
evidence review for oxygen treatment guidelines: what is the 
evidence supporting beneficial use of oxygen and at what 
threshold (oxygen saturation); and what is the best method for 
its delivery? For the latter consideration, for resource-poor set-
ting without access to intensive care (and mechanical ventilation), 
this will mainly consider non-invasive methods.
1.8.1 Who needs oxygen? A Cochrane review conducted in 
200513 and updated in 201434 examined evidence in the literature 
for: (i) indications for oxygen therapy, including both observa-
tional studies and RCTs comparing oxygen versus no oxygen 
therapy; and (ii) RCTs comparing methods of oxygen delivery 
for hypoxic LRTI in children aged three months to 15 years34. 
Of the 551 articles assessed, there was no study that compared 
delivering oxygen with not delivering oxygen. Of the eligible 
studies, four RCTs compared delivery methods (see section 1.12) 
and 14 observational studies assessed the accuracy of clinical signs 
for indicating hypoxaemia. The review found no single clinical 
sign or symptom accurately identified hypoxaemia, although pneu-
monia complicated by hypoxaemia increased the risk of death35. 
Wider implementation of pulse oximeters was recommended to 
identify those at greatest risk and for studies examining the most 
effective and safe method for oxygen delivery.
Thus, irrespective of the availability of mechanical ventilation, 
there have been no controlled trials of the use of oxygen supple-
mentation that have incorporated a randomisation strategy of no 
oxygen. In resource-poor settings, there are limited relevant data 
from epidemiological studies for children receiving oxygen, or 
not, However, a review of available literature indicated little dif-
ference in mortality in children with pneumonia and SpO2 >80% 
receiving or not receiving supplementary oxygen36. The only 
prospective observational study conducted to date examined 
mortality before and after improving systems for oxygen deliv-
ery in five hospitals in Papua New Guinea (that had no access to 
mechanical ventilation)10. The study found a lowering mortality in 
children with pneumonia from 5.0% (95% confidence interval 
(CI) 4.5–5.5) to 3.2% (95% CI 2.7–3.8) for the 27 months after 
the improved system was introduced. Estimated costs of this sys-
tem were US$51 per patient treated, US$1673 per life saved, and 
US$50 per disability-adjusted life-year averted16. Neverthe-
less, there are a number of alternative explanations for improved 
outcomes, including possible benefits from training, improvements 
in the delivery of emergency care and/or other components of 
treatment, patient monitoring or temporal changes, which limit 
generalisability since the study was not designed to address direct 
benefits to the individual.
1.8.2 Oxygen toxicity: The need for equipoise. Hypoxaemia 
is common amongst critically ill patients (with and without 
pneumonia) and usually is treated with oxygen and, where 
available and indicated, ventilatory strategies with the aim to 
restore arterial oxygenation to normal values and thereby reduce 
morbidity and mortality associated with hypoxaemia. This said, 
strategies used to treat hypoxaemic critically ill patients are also 
associated with harm, and this harm may outweigh the benefit 
of an increase in arterial oxygenation. Oxygen has been used in 
the treatment of pneumonia for a large part of the last century. 
However, the recognition of pulmonary oxygen toxicity as a 
problem has been relatively recent. Toxicity is related to the con-
centration of oxygen and length of exposure. Oxygen causes 
tracheobronchial irritation, reduced mucociliary function (even 
in healthy volunteers exposed to 90–95% oxygen for three 
hours37) and, eventually, adsorption atelectasis, decreased vital 
capacity and changes similar to adult-type respiratory distress 
syndrome38. The biochemical basis is considered to be due to 
damage to tissues through the production of reactive oxygen spe-
cies. For these reasons it is recommended that inspired oxygen 
concentration (FiO2) should be carefully titrated against SpO2. 
However, oxygen toxicity has wider consequences, beyond 
the pulmonary system with animal models showing reduction 
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coronary blood flow. Moreover, as haemoglobin is fully saturated 
with oxygen, supra-physiological oxygen tensions have little 
additional oxygen content compared to blood with physiological 
oxygen tensions.
1.8.3 Conditions in which oxygen therapy are no longer 
recommended. In several areas of emergency care and resus-
citation, emerging evidence from clinical trials and systematic 
reviews is now challenging the use of oxygen. In neonates, use 
of 100% oxygen during resuscitation increases mortality, myo-
cardial injury and renal injury39; even following an asphyxiating 
perinatal event, it is thought to increase the risk of cerebral 
damage40. Current resuscitation guidelines in neonates now advise 
that the initial gas administered for ventilation should be room 
air41.
In patients with an acute myocardial infarct, systematic reviews 
have found that, compared with room air, there is no evidence that 
oxygen therapy is of benefit42; this is similarly the case in patients 
with an acute stroke43. A recent trial in adults with asthma has 
shown that high concentration oxygen therapy results in a clini-
cally significant increase in carbon dioxide (CO2), recommending 
careful titration of oxygen and only to those who are hypoxaemic44. 
Much of the concern for optimising oxygenation has centred 
on neuroprotection or prevention of cognitive deficits in the 
long term, but the evidence supporting this is weak. In a follow-up 
study of mechanically ventilated adult patients with acute lung 
injury, a lower partial pressure of arterial oxygen (but not oxy-
gen saturation) was associated with cognitive impairment45. 
No equivalent studies are available for paediatric cohorts. 
A systematic review in children with chronic or recurrent hypox-
aemia indicated adverse effects on development, behaviour, and 
academic achievement; however generalising these findings 
are complicated since most studies had small sample sizes and 
did not stratify by SaO246.
With accumulating evidence that normoxaemia may not be a 
prerequisite to survival or successful recovery, opens up the 
possibility of permitting selected patients to remain hypoxic con-
sequent upon their disease. Permissive hypoxaemia describes 
a concept in which a lower level of arterial oxygenation than 
usual is accepted to avoid the detrimental effects of inspired 
oxygen47,48. No specific threshold is known that defines 
permissive hypoxaemia, and its use remains formally untested.
1.9 Evidence for a threshold for delivery of oxygen
We were unable to find any data that prospectively determined 
a threshold for delivery of oxygen; in any setting, only obser-
vational studies reported mortality for those with and without 
hypoxaemia. One review from 1993 examined mortality in his-
toric retrospective studies (1920’s) of children with acute respi-
ratory tract infection with or without oxygen therapy36. Whilst 
mortality rates were higher in those receiving and not receiving 
oxygen, these data are not informative since the a priori risk 
in the two groups are likely to be very different. In 2015, a 
parallel-group, randomised, controlled, equivalence trial of oxygen 
threshold strategies in infants aged 6 weeks to 12 months with 
clinician-diagnosed bronchiolitis was reported. The trial compared 
two strategies targeting an oxygen saturation threshold of 90% 
(n=308) and 94% (n=307). The primary outcome was time 
to resolution of cough (considered to reflect the degree of airway 
inflammation and thus influence the degree of hypoxaemia). In 
both arms, median time to cough resolution was 15 days (95% CI 
for difference –1 to 2), thus oxygen thresholds were equiva-
lent. Adverse events were similar in both arms26. The study con-
cluded that management of infants with bronchiolitis to an oxygen 
saturation target of 90% or higher is as safe and clinically 
effective; this suggested further studies in older children exam-
ining oxygen thresholds are needed, particularly in developing 
nations where resources are scarce. 
The WHO review of evidence, recommendation and key ques-
tions for future research is more comprehensive for the man-
agement of hypoxemia and oxygen delivery than any other 
of the WHO recommendations covering eight pages of the 
‘Technical update of pocket book: evidence review of WHO 
recommendations’12. Pertinent to the questions being addressed 
by the COAST trial are those examining the use of oxygen therapy 
and delivery systems. These are given under the actual number 
section headings contained within the review (pages 69–76):
    Section 10.3 Oxygen therapy in treatment of hypoxaemia 
(page 72)
 a) Children with hypoxaemia should receive appropriate oxy-
gen therapy. (Strong recommendation, low quality evidence)
 b) Effective oxygen delivery systems should be a universal 
standard of care, and should be made more widely available. 
(Strong recommendation, expert opinion)
    Section 10.4 Thresholds for administering oxygen therapy 
(page 73)
 a) Administering oxygen therapy should be guided by pulse 
oximetry where available and thresholds for giving oxygen 
may vary depending on the altitude. (Strong recommendation, 
very low quality evidence)
 b) Children living at ≤2500 m above sea level should receive 
oxygen therapy if their oxygen saturation is <90%. (Strong 
recommendation, very low quality evidence)
 c) In children living at high altitude (>2500m above sea 
level), the normal oxygen saturation is lower than those liv-
ing at sea level. At these altitudes, a lower level of saturation, 
such as SpO2 ≤87%, could be used as a threshold for giving 
oxygen. (Strong Recommendation, very low quality evidence)
In summary, most of the evidence for current recommendations 
is of very low quality; the use of oxygen is rated as expert 
opinion rather than based on evidence.
1.10 Evidence from other sources
1.10.1 Risk of mortality modelled against oxygen saturation. 
We examined the relationship between oxygen saturation at 
admission (or baseline) and mortality by 48 hours using 
a fractional polynomial logistic model restricted to the baseline 
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measure, in the Kilifi (KEMRI Wellcome Trust Programme) 
dataset of paediatric general admissions (n=36,036; unselected 
admissions) (Figure 2) (Maitland et al., unpublished data). The 
same relationship was also modelled and examined in more 
critically ill children using the control arm group of the FEAST 
Trial (n=1007) (Figure 3) (Maitland et al., unpublished data). The 
trial eligibility criteria included children with severe illness (and 
shock), thus is equivalent to the inclusive definition of VSP (res-
piratory distress (83%) and/or impaired consciousness (72%))24. 
Both datasets indicated a steady increase of risk of mortality 
as SpO2 decreases from 100% to 80%, with a much higher risk 
of mortality at around 80%. The wider 95% CIs at low values 
in the FEAST dataset are due to low numbers, but is less pro-
nounced for SpO2 ≥80%. Across the range 80–89% there were 
no statistical difference in the mortality (Day 2 mortality rates 
(Kilifi admission data) in children with COAST inclusion criteria: 
SpO2 of 80–82%(13%); 83–86%(10%); 87–89%(12%) (chi squared 
for trend P=0.5)).
Mortality in children with oxygen saturations 80–92% with 
severe febrile illness in the FEAST trial (control arm where not 
all children received oxygen) was 10% compared to 9% a KDH 
general admission population. For children with oxygen satura-
tions < 80% in hospital mortality in the respective cohorts was 
30% and 26%, respectively. Relevant to the design of the COAST 
trial is within the range 80–89% (<90% as per WHO guidelines 
where the oxygen-attributable preventable mortality (assuming 
that oxygen does prevent mortality) is very low because the 
mortality across this range of saturations is relatively flat with no 
statistical difference across the range.
1.11 Oxygen administration: Evidence for delivery methods
There are many ways of giving oxygen49,50; however, the 
WHO recommend NPs or NPCs for ease of delivery, patient 
acceptability and safety12. Facemask delivery of oxygen requires 
much higher oxygen flow rates (to wash out the CO2), and feed-
ing can interfere with its supply, thus is more costly. NPC 
requires the lowest oxygen flow rates, thus providing more 
reliable FiO2, but need careful insertion as, if misplaced, it could 
lead to gastric dilation or accidental dislodgement into the trachea. 
With NPs, a flow rate of 1–2 L/min in a child aged >4 months 
should provide a FiO2 of 30–35%; however, this varies with inspira-
tory flow, weight and degree to which the child breathes through 
their mouth51. These are important logistical issues for optimising 
oxygen delivery. The most widely used method of non-invasive 
oxygen support is nasal continuous positive airway pressure 
(CPAP) which has been investigated as an alternative strategy 
for endotracheal respiratory support in order to reduce to 
complications of mechanical ventilation in infants and pre-
term infants52. It has also been investigated as a method for 
respiratory support in low resource settings53.
1.11.1 High flow oxygen therapy. An alternative strategy 
than CPAP is high flow nasal cannula (HFNC) oxygen deliv-
ery. HFNC is a relatively newer form of non-invasive respira-
tory support that delivers a mixture of air and oxygen (blended 
gas) via dedicated bi-nasal cannula that fit snugly with the nares 
to minimise leakage. Heated, humidified, high-flow (such as 
AirVO2TM), deliver blended oxygen air at flow rates over 1 L/min 
through bi-nasal cannula which smaller than those of NCPAP and 
with prongs positioned to sit just inside the nares and do not pro-
vide a seal. It is more comfortable for the infant, results in less 
nasal trauma than other forms of respiratory support54, it is easy to 
implement and as a result increasingly used globally. HFNC 
results in incidental delivery of positive end expiratory pressure 
(PEEP)55–57. Whilst not fully understood it has been suggested 
that the high flow ‘flushes out’ pharyngeal dead space, resulting 
in a positive expiratory pressure effect, improved alveolar recruit-
ment and, greater humidification, and a better control of inspired 
oxygen fraction55,58. HFNC therapy has also been reported to be 
better tolerated by the patient than other forms of non-invasive 
ventilation, partly due to the use of HFNC oxygen therapy with 
heated and humidified gases59.
Some studies, but not all, have shown AirVO2TM oxygen devices 
reduce the requirement for positive pressure ventilation in the 
paediatric population with respiratory failure secondary to 
infection60,61. The AirVO2TM device (Fisher & Paykel Health-
Care) is adaptable for children over a wide weight and age range 
and is capable of providing sustainable, non-invasive respiratory 
support generating high flows through a self-contained turbine-
driven device (ACTRN12613000028707), without the need for 
specialized masks or endotracheal intubation – all of which are 
significant financial and technical barriers for use in resource-poor 
settings.
1.12 Trials and systematic reviews of oxygen delivery 
systems
A Cochrane review (update) conducted in 2014 identified four 
studies (479 participants) assessing the efficacy of non-invasive 
delivery methods for the treatment of pneumonia in children34. 
Three RCTs (399 participants) compared the effectiveness of 
NPs or nasal cannula with NPCs and one non-RCT (80 partici-
pants) compared head box, face mask, NPCs (control) and nasal 
cannula. The use of a face mask showed a statistically significant 
lower risk of failure to achieve arterial oxygen > 60 mmHg than 
the nasopharyngeal catheter (one non-RCT; 80 participants; odds 
ratio (OR) 0.20, 95% CI 0.05 to 0.88). The use of a head box 
showed a non-statistically significant trend towards a reduced 
risk of treatment failure compared to the NPC (one non-RCT; OR 
0.40, 95% CI 0.13 to 1.12). NPs are associated with fewer nasal 
obstruction problems. The quality of the evidence was judged to 
be very low.
1.13 Recent randomised controlled trials
The recent eight centre, 618 patient clinical trial in the UK (the 
Bronchiolitis of Infancy Discharge Study; BIDS26) showed that 
management of infants with bronchiolitis to an oxygen satura-
tion target of 90% or higher is as safe and clinically effective as 
one of 94% or higher. The authors suggested that future research 
should assess the benefits and risks of different oxygen saturation 
targets in acute respiratory infection in older children, particularly 
in developing nations where resources are scarce.
An open, randomised, controlled trial in a referral hospital in 
Dhaka in 225 children < 5 years with severe pneumonia and 
hypoxaemia randomized children to receive oxygen therapy by 
either bubble CPAP (5 L/min starting at a CPAP level of 5 cm 
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Figure 2. Relationship between baseline oxygen saturation and 48-hour mortality in 36,036 Kilifi paediatric general admissions.
Figure 3. Relationship between baseline oxygen saturation and 48-hour mortality in the FEAST control arm (n=1007).
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H2O), standard low-flow nasal cannula (2 L/min), or high-flow 
nasal cannula (2 L/kg per min up to the maximum of 12 L/min)53. 
The primary outcome was treatment failure (i.e.clinical failure, 
intubation and mechanical ventilation, death, or termination of hos-
pital stay against medical advice) after more than 30 minutes of 
treatment. In total, 79 (35%) children were randomized to receive 
oxygen therapy by bubble CPAP, 67 (30%) to low-flow oxygen 
therapy, and 79 (35%) to high-flow oxygen therapy. The trial 
was stopped twice once after the first interim analysis and finally 
after the second interim analysis after only 25% of the predicted 
sample size were enrolled, on the recommendation of the data 
monitoring committee. Treatment was declared to have failed 
for 31 (14%) children, of whom five (6%) had received bubble 
CPAP, 16 (24%) had received low-flow oxygen therapy, and ten 
(13%) had received high-flow oxygen therapy. Treatment failure 
was lower in the CPAP group than in the low-flow oxygen therapy 
group (relative risk [RR] 0.27, 99.7% CI 0.07-0.99; p=0.0026). No 
difference in treatment failure was noted between patients in the 
bubble CPAP and those in the high-flow oxygen therapy group (RR 
0.50, 99.7% 0.11-2.29; p=0.175). 23 (10%) children died. Three 
(4%) children died in the bubble CPAP group, ten (15%) children 
died in the low-flow oxygen therapy group, and ten (13%) chil-
dren died in the high-flow oxygen therapy group, indicating that 
bubble CPAP group had significantly lower rates of death than 
the children who received oxygen by low-flow oxygen therapy 
(RR 0.25, 95% CI 0.07-0.89; p=0.022). The authors concluded that 
bubble CPAP improved outcomes in Bangladeshi children with 
VSP and hypoxaemia compared with standard low-flow oxygen 
therapy, but the early cessation of the trial reduces the certainty 
of the findings and suggested that further research was required 
before guidelines could be changed.
An accompanying editorial was highly critical of the early stop-
ping of the trial flagging the perils of early stopping for apparent 
efficacy62,63, which may provide misleading results and that small 
sample sizes can lead to random variation often causing large 
treatment effects (randomly either spuriously too high or too low) 
that diminish as the trial progresses (widely recognised as ‘regres-
sion to the truth’)64. Quoting from an authority on clinical trial 
methodology, the editorial recommended to “Avoid any analysis 
(or even brief inspection) of the data until some dozens of deaths 
have accumulated, for it is trials first looked at when the number of 
events are very small that are most likely to be misleading’’65. This 
author had developed the Haybittle-Peto rule for early stopping of 
a trial (indicating a p value of <0.001)65. An independent statisti-
cian had recommended, after the trial was initially stopped after the 
first interim analysis, in future to use a stopping rule with p value 
<0.003; this advice was not taken. Furthermore, there are con-
cerns that the rescue strategy in the protocol for children for 
whom low-flow oxygen therapy failed would have a trial 
of bubble CPAP or high-flow oxygen therapy before intubation 
and mechanical ventilation, which was the standard rescue therapy 
for CPAP and high-flow arms.
1.14 Rationale for a controlled trial
The high incidence and mortality associated with hypoxaemia 
in children with pneumonia and severe illness at hospitals 
constitutes a major public health challenge. Options for support-
ive care in hospitals without access to mechanical ventilation are 
limited. At present, there is uncertainty as to what the best cut-
off threshold for cost-effective oxygen delivery is and whether 
the addition of high flow is safe and results in improved 
outcome. Since hypoxaemia is so common and treatment costs 
and practicalities for optimal delivery of oxygen are complex, the 
COAST trial will contribute substantial new knowledge in this 
area. The COAST trial was proposed and discussed at the launch 
meeting of ISARIC in Annecy, July 2012. The meeting brought 
together many leading researchers and clinical trialists in severe 
respiratory illnesses with representation from international 
agencies, such as the WHO. The proposal had wide support as 
it was anticipated that the trial would result in refinements to the 
current WHO recommendations and provide robust evidence to 
support the targeting of oxygen to those with the greatest need 
and averting unnecessary consumption in financially constrained 
hospitals. The pragmatic nature of COAST and locations chosen 
will mean that the results of the trial will be immediately 
generalisable. The successful conduct of the FEAST Trial acts 
as a pilot for the conduct of COAST. The proposed high flow 
oxygen delivery device is in current use in South Africa, and 
feasibility testing and staff training in the COAST sites will 
occur before trial commencement. The COAST trial was pre-
ceded by the Paediatric Oxygenation Strategies Treatment Study 
(POST), a feasibility study, which assessed feasibility of both 
the intervention and the RCT processes (including testing 
whether high flow oxygen via the AirVO2TM device can be used 
effectively in a hospital in Africa). The POST study helped inform 
the trial protocol for COAST (Maitland et al., manuscript in 
preparation).
1.14.1 Research gap: Timeliness for a clinical trial. The inter-
national charity Lifebox launched a campaign to close the global 
‘pulse oximetry gap’ (Make It Zero). As more hospitals acquire 
pulse oximeters, the hidden ‘hypoxaemia burden’ will be rec-
ognised and demands for an equitable supply of oxygen will 
increase. A recent commission from a collaboration between The 
Lancet and Imperial College, examining how medical technol-
ogy could be used to improve health in low- and middle-income 
countries, identified technologies, such as oxygen delivery, as 
future priorities66. Nevertheless, important lessons were learnt 
in the FEAST Trial where fluid resuscitation, part of emergency 
care for decades in well-resourced countries, resulted in worse 
outcome in the fluid bolus arms24. Simple translation of established 
medical practice, largely based on a low quality of evidence, to 
resource-poor countries should be preceded by definitive trials to 
generate the evidence for best practice and cost-effectiveness. The 
COAST trial will provide the relevant evidence supporting such an 
initiative.
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PICO: Population – Intervention – Comparison – Outcome
Population Intervention Comparison Outcome
-     Pregnancy 
-      Patient Currently 
Pregnant
-     Pregnancy Nos 
-     Newborn 
-     Twin Pregnancy
-     Cesarean Section 
-      Vaginal Delivery 
Of Fetus
-      Providing Care 
According To 
Standard
-     Cesarean Section 
-      Vaginal Delivery  
Of Fetus
-      Providing Care 
According To 
Standard
To learn more about PICO – please visit https://en.wikipedia.org/wiki/PICO_process
2. Trial protocol
3.2 Secondary
The secondary outcome measures are:
•    Treatment failure at 48 hours (i.e. still receiving oxygen/ 
respiratory support)
•    Survival to 28 days
•    Neurocognitive sequelae (de novo or worsening of existing 
neurological impairment) at 28 days
•    Disability-free survival to 28 days
•    Time to hypoxaemia (≥92%) resolution during initial hospital 
stay
•    Length of initial hospital stay
•    Re-admission to hospital by 28 days
•    Anthropometric status by 28 days
•    Resolution of neurocognitive sequelae at 90 days (for those with 
neurocognitive sequelae at 28 days (see above))
3.3 Trial design
COAST is an open, multicentre, fractional factorial RCT of 4,200 
participants, aged from 28 days to 12 years, admitted to hospital 
with respiratory distress complicated by hypoxaemia. Participants 
will be enrolled over a 30-month period and followed up to 28 days 
post-randomisation (and at 90 days for those with neurocognitive 
sequelae at 28 days).
3.4 Benefits and risks
3.4.1 Benefits. In conducting COAST, we will identify the hidden 
burden of hypoxaemia; therefore, more children are likely to benefit 
than if the trial was not conducted in the first place. In FEAST, we 
witnessed substantial improvements in outcomes in the hospitals 
where the trial was taking place. Outcomes of participants in trials 
are often substantially improved. Extra clinical personnel, regular 
patient clinical assessment and the basic equipment for continuous 
patient monitoring are available during the trial so that if the com-
plications above were to arise they could be detected and treated. 
Pre-trial training to include sign recognition for these complications 
and training on treatment. Both these are covered in detail in the 
Manual of Operations, which will be available on the ward.
2.1 Trial aim and objectives
The COAST trial will investigate what the best oxygen delivery 
strategies are to reduce in-hospital mortality and morbidity in Afri-
can children with respiratory distress complicated by hypoxaemia 
(defined as SpO2 <92%). This will be done by evaluating two linked 
components of oxygen delivery:
1.   whether liberal oxygenation is superior to permissive 
hypoxaemia (current routine standard of care in hospitals 
not screening all admissions for hypoxaemia); and
2.   whether high flow oxygen delivery is better than low 
flow oxygen delivery (current routine standard of care in 
hospitals with no access to mechanical ventilation).
Both the primary and secondary objectives will address what 
threshold to deliver oxygen (above a threshold of SpO2 ≥80%).
2.2 Primary objectives
To establish whether:
•    liberal oxygenation will decrease mortality compared with 
permissive hypoxaemia (usual care); and
•    high flow oxygen delivery will decrease mortality compared 
with low flow oxygen delivery (usual care).
2.3 Secondary objectives
The secondary objectives of COAST are:
•    to assess the effectiveness in the speed and success of 
recovery from the initial respiratory failure;
•    to assess safety and quality of life;
•    to determine long-term effects of the delivery strategies; 
and
•    to identify whether the additional costs of each of the 
interventions are proportionate to the health benefits and 
to inform future widespread implementation in terms of 
value for money.
3. Trial outcome measures
3.1 Primary
The primary outcome measure is mortality at 48 hours 
post-randomisation.
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3.4.1.1 For the child
The direct benefits to the child and/or family (outlined in the Patient 
Information Sheet, Supplementary File 1) include:
•    The consent process, as in the FEAST Trial67, will allow 
parents/guardians time to weigh up benefits and risks before 
giving deferred consent.
•    Closer observation during the first 48 hours of 
admission, which, as a result, allows doctors and nurses 
to make important changes to the child’s treatment during 
in-hospital admission.
•    All routine non-trial medications required by the hospital 
to treat the child will be made available (when unavailable, 
parents/guardians will have to resort to sourcing these 
privately).
•    The parents/guardians of participating children will 
be asked to return for follow-up at 28 and 90 days after 
admission (only for those with suspected neurological 
sequelae at Day 28). Reimbursement for transport cost 
after discharge and for follow-up visits, plus any treatment 
costs required during the visits, will be made.
3.4.1.2 For the hospital
The direct benefits to the hospital include:
•    Substantial investment in training and provision of equip-
ment and consumables to provide oxygen will improve the 
treatment of all critically sick children.
•    Pulse oximeters will routinely be used in triage, thus 
improving the specificity of the clinical criteria for 
oxygen-use – this can then be directed to those with 
hypoxaemia and reduce potential wastage of this resource 
to children who do not require oxygen therapy.
•    Additional staff, employed directly for the trial, who are 
likely to manage the sickest patient (those at high risk of 
hypoxaemia and thus eligibility for the trial), will help 
relieve the treatment burden on acute paediatric services.
3.4.1.3 For health personnel
The direct benefits to health personnel are mainly professional 
development of the members of the trial teams and clinical 
teams for the purposes of running the trial, including basic life 
support courses, clinical trials training and research training.
3.4.2 Risks
3.4.2.1 Oxygen saturation threshold
Children are carefully monitored, including active reporting 
of solicited adverse events (AEs). Training of trial staff, as in 
FEAST, to ensure that trial participants receive recommended 
standard of care and careful monitoring. Expected inherent 
hazards of the intervention strategies, solicited and serious 
adverse events (SAEs), as defined by ICH-GCP guidelines, are 
secondary outcomes of the trial; these will be reported in 
real time and assessed by an independent Endpoint Review 
Committee (ERC). We have included within the protocol oxygen to 
be given (by low flow) for all children whose saturations are ever 
<80% to minimise harm. The ICH-GCP compliant SAE data 
collection and reporting procedures will be adopted. Clinical staff 
at sites will be trained by the Chief Investigator (ChI) and training 
team at the initiation visit to recognise expected side effects.
3.4.2.2 High flow versus low flow
High flow is an accepted strategy in the management of children 
with respiratory failure in a multitude of countries, with few reports 
that it is unacceptable, so the risks of harm from this strategy 
are known and are extremely low.
3.4.2.3 Deficiencies in oxygen supply
We will use bottled oxygen, whenever this is available. 
When supplies are low, we will use oxygen concentrators (at least 
three per site) and a reliable ‘power back’ system of electricity. 
The backup system will use a bank of batteries and charge dur-
ing periods of electricity supply. If there are power outages, it will 
automatically switch on to provide backup power for up the 
12 hours. If there are long periods of power outages (though unu-
sual), then the trial teams will stop screening patients and not 
enroll into the trial until power is restored. A maximum of 
four patients per day will be recruited to alleviate potential 
burden on the available oxygen supplies so that this can be used 
in children outside of the trial (including cases where consent 
is declined).
4. Selection of sites
Five hospitals in two countries will participate:
•    Kenya: KEMRI Wellcome Trust Programme, Kilifi  
County Hospital (KCH). The clinical programme at KCH is 
a well-established research centre on the coast of Kenya. It 
has been the site of several clinical studies on severe malaria, 
including two large phase III trials (AQUAMAT and FEAST). 
Coast Provincial General Hospital (CPGH) is based in the 
second largest city in Kenya (Mombasa) and has conducted in 
collaboration with KWTRP a number of research studies and 
Phase III clinical trials in children admitted to CPGH.
•    Uganda: Mulago National Referral Hospital, Mbale 
Regional Referral Hospital and Soroti Regional Referral 
Hospital. Mulago, Mbale and Soroti hospitals have annual 
admissions to the paediatric ward of 18,000, 20,000 and 
8000, respectively. There has been considerable research 
capacity development in the last five years, with these 
three sites involved in the FEAST trial and currently conducting 
a large multicentre trial of transfusion trial (TRACT).
The five centres in Africa represent a spectrum of intensity of 
malaria transmission, from perennial and high (in Mbale and 
Soroti) to seasonal and meso-endemic (in Kampala, Mombasa and 
Kilifi). Mulago and CPGH are located within large urban areas, 
whereas the populations that utilise Mbale, Soroti and Kilifi are 
more typically rural; however Mbale has a few slum developments 
within the town.
Central grant funding will be available for participating sites. 
To participate in the trial, selected hospitals and principal 
investigators (PI) must fulfil the criteria defined below.
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4.1 Site/investigator inclusion criteria
The site/PI should:
1.   Be qualified by education, training, and experience to assume 
responsibility for the proper conduct of the trial at their site 
and should provide evidence of qualifications through an 
up-to-date curriculum vitae (CV) and/or other relevant docu-
mentation requested by the Sponsor, the Research Ethics 
Committee (REC) or Institutional Review Boards (IRB) and/or 
the regulatory authority(ies).
2.   Be aware of, and should comply with, the principles of ICH-
GCP and the applicable regulatory requirements. A record of 
GCP training should be accessible for all trial staff at the site.
3.   Have available or appoint an adequate number of qualified 
staff for the duration of the trial to conduct the trial properly 
and safely. Trial staff should be adequately informed about the 
protocol, trial equipment and their trial-related duties. The site 
should maintain a Delegation Log of appropriately qualified 
persons to whom the PI has delegated trial-related duties.
4.   Be able to demonstrate a potential for recruiting the required 
number of participants and have sufficient time to conduct the 
trial as per protocol and complete the trial within the agreed trial 
period.
5.   Permit monitoring and auditing by the Sponsor, and 
inspection by the appropriate regulatory authority(ies).
4.2 Documentation
The following documentation must be in place prior to a trial site 
being opened to recruitment:
•    Investigator Statement – this verifies that the site is willing 
and able to comply with the requirements of the trial and 
will be signed by the site PI;
•    Signature Form – this will be signed by site staff delegated 
trial responsibilities by the PI; and
•    Delegation Log and staff contact details.
All completed documents should be sent to the Kilifi Clinical 
Trial Facility (KCTF). Up-to-date copies of the Delegation Log 
and contact details (with any changes to trial personnel and/or 
their responsibilities) should be sent to the KCTF and a copy should 
be stored in the Investigator Site File (ISF) at the site.
4.3 Activation
On receipt of all the documents, written confirmation will be sent 
to the PI, at which point the site may start to screen for eligible 
patients.
Once the site is activated, they should ensure:
•    adherence to the most recent version of the protocol;
•    appropriate recruitment and care for participants in the 
trial;
•    timely data entry; and
•    prompt notification of all AEs and protocol deviations to the 
trial team at the KCTF.
5. Selection of participants
5.1 Screening
The trial will run 24 hours/seven days per week. Patients will be 
assessed for eligibility at the point of hospital admission by the 
dedicated and trained trial nurse or clinician (on trial delegation 
log). Established triage systems will identify potential patients 
who will be screened against the inclusion/exclusion criteria; 
a member of the trial team will carry out a rapid structured 
assessment of heart rate, oxygen saturation (pulse oximetry), res-
piratory rate, axillary temperature, blood pressure, markers of 
shock (capillary refill time, pulse volume and assessment of 
lower limb temperature) and severity (conscious level and 
respiratory distress). Entry criteria will be based on clinical 
assessment alone; it is anticipated that this process will take 
five minutes.
Infants and children aged between 28 days to 12 years who are 
potentially eligible for inclusion will be fast tracked to the trial 
team for full eligibility screening and assent/consent for enrol-
ment. Children who do not meet the eligibility criteria at initial 
assessment will be re-screened for eligibility up to 24 hours 
post-hospital admission.
Sites will maintain a record of all patients who are screened for 
eligibility for COAST:
•    Eligibility Screening Log – will record all potentially 
eligible patients (who fulfil the inclusion criteria, but meet 
one or more of the exclusion criteria); and
•    Screening Form – will record all patients who meet the full 
eligibility criteria (with reasons for non-randomisation).
5.2 Inclusion criteria
•    Aged between 28 days to 12 years
•    History of respiratory illness (cough, upper respiratory tract 
symptom or any respiratory symptoms, e.g. rapid breathing 
or increase work of breathing)
•    Hypoxaemia (pulse oximetry reading of SpO2 <92% 
recorded in room air over 5 minutes)
a.    Plus suspected severe pneumonia informed by WHO 
guidelines, as below - Sign of respiratory distress (any 
one of):
o severe lower chest wall in-drawing
o use of auxiliary muscles
o head nodding
o  inability to feed because of respiratory 
problems
b. Suspected pneumonia
o  fast breathing:
▪  age 2–11 months: ≥ 50/minute
▪  age 1–5 years: ≥ 40/minute
▪  age 5–12 years ≥ 30/minute
o  chest auscultation signs:
▪  decreased breath sounds
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▪  bronchial breath sounds
▪  crackles
▪   abnormal vocal resonance (decreased over 
a pleural effusion or empyema, increased 
over lobar consolidation)
▪  pleural rub
c. Signs of pneumonia with a general danger sign:
o  inability to breastfeed or drink
o  lethargy or unconscious
o  convulsions
5.3 Exclusion criteria
•   Known uncorrected cyanotic heart disease
•   Assent/consent refusal by parent/carer
•   Previously recruited to COAST
•    Already received oxygen for this episode of illness (at 
another health facility)
•   Known chronic lung disease (not including asthma)
6. Enrolment
6.1 Consent
Once eligibility has been confirmed, authorised trial staff will 
approach parents/guardians to invite their child to take part in 
the trial. An information sheet will be provided to the parent/ 
guardian in their usual language containing details of the 
COAST trial. The sheet will be read aloud to those who are 
unable to read. The doctor/nurse will check that the information 
has been fully understood and parents/guardians will be 
encouraged to ask questions they may have about their child’s 
participation in COAST.
Where possible, prospective written informed consent will be 
sought from parents/guardians who will then be asked to sign the 
Consent Form. If parents/guardians are unable to sign, a thumbprint 
will be taken in lieu of a signature.
If it is considered that the full consent process would signifi-
cantly delay treatment allocation, and consequently be detrimen-
tal to the child’s health, then emergency verbal assent, used in the 
FEAST and TRACT trials67, will be sought from parents/ 
guardians by the admitting medical team (see section 7.2).
6.2 Emergency verbal assent followed by deferred consent
It is likely that, due to the emergency nature of the patients’ condi-
tion, the full consent process may delay treatment. If this is the 
case, then parents/guardians will be provided with a brief verbal 
description of the trial and will be given the opportunity to “opt out” 
of clinical research. Full consent will be sought once the child’s 
clinical condition has been stabilised. The clinician will later sign 
the Verbal Assent Form, (Supplementary File 2) which will be 
filed with the Consent Form. If consent is withdrawn later, trial 
data collected up to the time of withdrawal will only be used 
and no further trial specific procedures will be conducted (see 
section 7.5).
A copy of the Consent Form will be given to the parent/ 
guardian, the original placed in the patient’s medical notes, and 
a copy kept in the Investigator Site File.
6.3 Randomisation
The trial has two strata: COAST A: severe hypoxaemia, SpO2 
<80%); and COAST B: hypoxaemia (SpO2 ≥80% and <92%).
Children in COAST A (2-arm, 1:1 ratio) will all receive oxygen and 
randomisation will allocate participants to one of two methods of 
oxygen delivery:
 i. high flow oxygen delivery
ii. low flow (usual practice) oxygen delivery
Children in COAST B (3-arm, 2:1:1 ratio) will be allocated to
  i.   permissive hypoxaemia (no immediate oxygen); control
 ii.   high flow oxygen delivery
iii.   low flow (usual practice) oxygen delivery
Participants will be allocated to treatment arms by a computer-
generated list using random permuted blocks. The blocks will 
be stratified by trial site and baseline SpO2 <80% or ≥80%. The 
Trial Statistician at the Intensive Care National Audit & Research 
Centre (ICNARC) Clinical Trials Unit (CTU) will prepare the 
randomisation lists before the trial commences and kept at the 
ICNARC CTU, London. Opaque and sealed randomisation 
envelopes will be prepared and provided to each site, with one 
set for COAST A (SpO2 <80%) and one set for COAST B (SpO2 
≥80% and <90%). The envelopes for each site will be numbered 
consecutively and opened in numerical order. These will contain 
details of the treatment arms once opened.
This system has worked well in the emergency care trials, 
i.e. FEAST and TRACT (transfusion trial). To facilitate protocol 
adherence, a maximum per site will be agreed upon (for example 
up to 4 children per day) will be enrolled per site. This approach 
was very successful with respect to protocol adherence and the 
quality of data generated in the FEAST trial.
6.4 Co-enrolment
Participants will not be permitted to co-enroll in any other inter-
ventional studies while on COAST. Participation in studies that 
do not involve an intervention (e.g. observational studies) are 
acceptable, but should be discussed with the COAST Trial 
Meeting Group (TMG). The TMG will consider co-enrolment of 
COAST participants onto other observational studies where the 
management does not conflict with the COAST objectives on a 
case-by-case basis.
6.5 Withdrawal
In consenting to the trial, parents/guardians and their children 
are consenting to trial treatment, assessments, data collection 
and follow-up. However, children or their parents/guardians can 
withdraw from COAST at any time during the trial.
If a child, or their parents/guardians, chooses to withdraw any 
part of their trial treatment, they should always be followed-up 
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and encouraged not to leave the full trial. The treating clinician 
remains free to give alternative treatment to that specified in the 
protocol at any stage if he/she feels it is in the participant’s best 
interest, but the reasons for doing so should be recorded. In 
these cases, the participants will remain within the trial, and all 
data collected up to the point of withdrawal will be retained for 
the purposes of follow-up and primary outcome data collected 
and included in the trial analysis.
If a child, or their parents/guardians, no longer wishes to take 
part or contribute further data to the trial (e.g. follow-up), their 
decision must be respected. A withdrawal form should be 
completed and sent to KCTF. Withdrawal of the participant should 
be recorded in their medical notes and no further data will be 
collected.
All identifiers will be removed at the end of the trial to ensure 
anonymity for all participants recruited into COAST.
7. Trial treatment
7.1 Randomisation allocation and treatment arms
The trial has two strata: COAST A: severe hypoxaemia, 
SpO2 <80%); and COAST B: hypoxaemia (SpO2 ≥80% and 
<92%). Patients will be assessed on severity of their hypoxaemia 
(SpO2 <92% initially recorded over 5 minutes in children breathing 
room air) and assigned to their severity stratum (Figure 4).
If baseline SpO2 is below 80% (severe hypoxaemia), patients will 
be enrolled into COAST A (Figure 5).
If baseline SpO2 is between 80–91%, which remains for 
10 minutes (i.e. an additional 5 minutes to initial screening) 
in children breathing room air (in order to mitigate against the 
possibility of a transient hypoxaemia or development of severe 
hypoxaemia), patients will be enrolled into COAST B (Figure 6).
For children after 10 minutes reassessment, SpO2:
•    drops below 80%, patients will be eligible for COAST A 
and randomised accordingly;
•    if ≥92% at admission patients will remain eligible for 
up to 24 hours post hospital admission (so long as the 
patient has not received oxygen). After 24 hours patients 
are no longer eligible, irrespective of SpO2.
The reassessments conducted within the 24-hour time window 
will prevent recruiting patients with only transient episodes of 
hypoxaemia (e.g. accompanying hypoglycaemia or convul-
sions which resolved on appropriate treatment) and allow for 
recruitment of children who subsequently develop hypoxaemia 
early into their hospital admission.
Usual emergency care will be provided as part of standard 
clinical management.
Trial treatments:
 i.   Low flow oxygen until oxygen saturation ≥92% in room air
ii.   High flow oxygen by AirVo2 TM until oxygen saturation ≥92% 
in room air, or the participant will switch to low flow oxygen 
(usual care) if:
•  High flow oxygen delivered for a maximum of 48 hours; 
if oxygen is still required at this point then the child will 
be switched to oxygen delivery by low flow (i.e. standard 
of care)
•  Unable to tolerate high flow oxygen provided indices of 
ventilation are optimal
Extra clinical personnel, regular patient clinical assessment and 
the basic equipment for continuous patient monitoring will be 
available during the trial so that if complications were to arise they 
could be detected early and treated. Pre-trial training will include 
sign recognition for these complications and training delivery of 
treatment.
All trial participants will receive standard of care, including 
antibiotics (intravenous or oral) and anti-malarial drugs fol-
lowing national guidelines, based on WHO syndromic patient 
management27.
7.2 Duration of treatment
The trial treatment period will last for a maximum of 48 hours 
post-randomisation. After this time point, the participant will switch 
to usual care (standard clinical management).
For children receiving oxygen delivered by high flow oxygen, 
at 48 hours, if oxygen is still required (i.e. failure to wean into 
room air) at this point, then the child will be switched to oxygen 
delivery by low flow (i.e. standard of care).
During the 0–48 hour period, if a child is unable to tolerate high 
flow oxygen and if oxygen is still required (i.e. failure to wean into 
room air), then the child will be switched to oxygen delivery by low 
flow (i.e. standard of care).
If oxygen is discontinued before 48 hours e.g. hypoxaemia is 
resolved (SpO2≥92% measured continuously over 30 minutes27), 
then they will switch to usual care (standard clinical management) 
following a successful trial of oxygen weaning.
Once weaning has occurred further clinical and bedside 
monitoring will occur twice daily until hospital discharge.
7.2.1 Standard clinical management. All other care will be 
determined by the clinical team primarily responsible for the 
participant’s care.
7.3 Trial equipment
Reliable sources of oxygen and bedside equipment for patient 
monitoring will be provided for the duration of the trial.
High flow oxygen will be delivered by the AirVO2TM device; 
AirVO2TM is manufactured by industry leaders Fisher & Paykel 
Healthcare. The device, complete with consumables, will be pro-
vided to each participating site. The AirVO2TM device can be used 
from bottled oxygen and has an inflow for concentrator-delivered 
supplemental oxygen. The device is already adaptable for 
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Figure 4. Trial flow chart.
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Figure 5. COAST A: Treatment arms.
Figure 6. COAST B: Treatment arms.
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children over a wide weight and age range and is capable of 
providing sustainable, non-invasive respiratory support generating 
high flows through a self-contained turbine-driven device. Medical 
and nursing staff will be able to operate the machine with minimal 
training. Fisher & Paykel will also provide technical support 
during the trial. The AirVO2TM device will only be used for patients 
randomised to receive high flow oxygen delivery.
In addition, oxygen saturation measurement will be undertaken 
by pulse oximeters. Up to 10 pulse oximeters will be provided 
per site. The pulse oximeter is a handheld device for use in the 
operating room, recovery unit and ward areas. It is both battery 
powered (3 AA alkaline batteries) or mains powered (nickel-metal 
hydride rechargeable battery or a lithium ion rechargeable 
battery). The standard battery use is approximately 14 hours.
8. Data collection
8.1 Data collection – participants (Table 2)
8.1.1 Baseline – characteristics. Following consent and 
randomisation(s), data will be collected on:
•    date and time of hospital admission
•    eligibility criteria
•    date and time of consent
•    patient identifiers
•    patient sociodemographics
•    oxygen saturation level
•    pre-existing neurocognitive deficits
•    hospital admission diagnosis and category
•    suspected cause of respiratory distress
•    severity of dyspnoea (assessed using an age-adjusted 
integrated respiratory distress and wheeze score68)
•    co-morbidities
•    severity of illness score
•    child’s ability to tolerate oxygen using an analogue scale69
8.1.2 Baseline – laboratory tests. Admission blood samples will be 
taken for the following investigations:
•    full blood count, urea and electrolytes
•    lactate
•    glucose
•    malaria blood slide and/or malaria RDT
•    white cell and red cell pellet (for subsequent DNA 
extraction)
•    blood culture (where culture facilities are available)
Table 2. Participant data collection schedule.
TRIAL PERIOD
Enrolment 
and  
Allocation
Post-allocation
TIMEPOINT Day of   admission Hour 0 Hour 1 Hour 2 Hour 4 Hour 8 Hour 12 Hour 24 Hour 36 Hour 48
Hospital  
discharge Day 28
ENROLMENT:
Eligibility 
screening X
Informed consent X*
Allocation X
ASSESSMENTS:
Baseline data X X
Diagnostic 
investigations X X
Laboratory/point of 
care diagnostics X
Hospital stay data X X X X X X X X X
Primary outcome X
Secondary 
outcomes X X X
Cost-effectiveness 
outcomes X X
*as soon as feasible
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•    nasal and oropharyngeal swabs and saliva specimen 
(for pathogen diagnosis)
•    plasma storage (acute serology; markers of immune 
markers)
•    EDTA x 2: for haemoglobinopathies and molecular 
pathogen diagnostics
Chest x-rays will also be taken when the patient is stable. In 
accordance with national guidelines, HIV testing will be 
performed after admission procedures are complete and assent 
given by parents or guardians. Pre- and post-test counselling will 
be done in accordance to routine practice
8.1.3 Hospital stay. All participants will be reassessed clinically at 
1, 2, 4, 8, 12, 24, 36 and 48 hours post-randomisation, and twice 
daily thereafter until discharged from hospital. At each review, the 
following will be recorded:
•    conscious level
•    vital signs (heart rate, oxygen saturation and percentage, 
respiratory rate, axillary temperature, blood pressure)
•    severity of dyspnoea (assessed using an age-adjusted inte-
grated respiratory distress and wheeze score68)
•    oxygen received and delivery method
•    prescribed drugs received
•    volume and type of intravenous fluid (including blood trans-
fusion) per 24 hours
•    AEs
8.1.4 Hospital stay – additional laboratory tests. Additional 
blood samples will be taken at the discretion of the clinical 
team at other times during the hospital stay if deemed necessary 
for a clinical deterioration for the following investigations:
•    haemoglobin
•    blood glucose
•    lactate
8.1.5 Hospital discharge
•   final diagnosis
•   discharge status
•   discharge date and time
All clinical staff members must follow all national and international 
guidance on hospital discharge tests and procedures27.
Children, or their parents/guardians, will receive a follow-up 
clinic visit invitation on a card; the date will be 28 days after the 
day of randomisation. Transport costs after discharge and for the 
follow-up visit will be reimbursed to parents/guardians by the 
trial site coordinator. Children who are still an in-patient at 28 days 
will be followed up in hospital.
8.1.6 Follow-up. A symptom checklist and targeted physical 
examination will be performed at the clinic visit scheduled for 
28 days after the day of randomisation.
•    Medical history since last visit, including hospital 
re-admissions, transfusions and SAEs
•   Convalescent sampling (plasma)
•    Neurocognitive function assessment (using the Developmental 
Milestones Checklist and an adaptation of the Kilifi  
Developmental Inventory70,71)
Any participant lost to follow-up before 28 days will be traced 
for vital status (using locator data and mobile telephone contacts 
taken prior to discharge).
Participants with evidence of neurocognitive sequelae at 28 days 
will also be followed up again at 90 days.
8.1.7 Health economics. The trial will measure healthcare-related 
costs for the trial participants, starting at randomisation and 
continuing for the duration of follow-up.
•    Costs incurred by the participants and their families (e.g. 
transport, indirect and companion person’s costs)
•    Information on hospitalisation (e.g. number, reason, and 
duration of stay)
•    Data on other healthcare resource utilisation (e.g. outpatient 
visits, medications, and procedures)
8.1.8 Outcomes
Primary outcome
Survival status will be recorded at 48 hours post-randomisation. 
Any participants lost to follow-up before 48 hours, without 
withdrawing consent, will be traced for vital status.
Secondary outcomes
•    Treatment failure will be defined as continued SpO2 
<92% in the presence of respiratory distress (indrawing or 
intercostal retractions) at 48 hours post-randomisation.
•    Survival status will be recorded at 28 days post- 
randomisation. Any participants lost to follow-up before 
28 days, without withdrawing consent, will be traced for vital 
status.
•    Neurocognitive sequelae will be defined as the development 
of a new neurocognitive deficit, assessed using the modified 
Kilifi Developmental Index, between the day of admission 
and 28 days following randomisation.
•    Composite disability-free survival will be defined as a change 
to disability-free status, between the day of admission and 
28 days following randomisation.
•    Time to hypoxaemia resolution will be defined as the 
duration in hours from randomisation to hypoxaemia resolution, 
defined as SpO2 ≥92% measured continuously over a period 
of 30 minutes during initial hospital stay.
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•    Duration of respiratory support will be defined as the number of 
days alive and free from receipt of administered oxygen during 
the first 28 days following randomisation.
•    Length of initial hospital stay will be defined as the duration in 
days from randomisation to initial hospital discharge.
•    Re-admission to hospital will be defined as hospitalisation (at the 
trial centre or other health facility) for acute illness (i.e. not due 
to an existing illness or an elective admission) between discharge 
and 28 days following randomisation.
•    Anthropometric status will be defined by Z-scores of height, 
weight and mid-upper arm circumference and any evidence of 
visible severe wasting or signs of kwashiorkor.
•    Resolution of neurocognitive sequelae will be defined as the full 
resolution by Day 90 of any neurocognitive deficit reported at 
Day 28.
•    Resource use and costs will be assessed using the methods 
previously described (see section 8.1.7) at 28 days following 
randomisation.
8.2 Data collection – site staff
8.2.1 Nurses. Nurses will be responsible for collecting data col-
lected at each clinical review during the hospital stay.
8.2.2 Doctors. During the initial hospital stay, a doctor will review 
the participant routinely (at the time points listed above) using a 
symptom checklist and targeted physical examination (to evaluate 
any reported symptoms). Additional reviews will be done where 
clinically indicated and recorded in the case notes.
8.2.3 Trial site coordinator. The trial site coordinator will be 
responsible for completing the Case Report Forms (CRF), follow-
ing up any data queries and tracing the results of pending laboratory 
tests.
9. Data management
Each site will be responsible for its own data entry using the 
COAST CRF (Supplementary File 3). After 48 hours, the hospital 
patient’s notes will be used in place of the CRF; a COAST trial 
number sticker will be added on the front page of the patient’s 
hospital notes and a caption “COAST trial participant: Notes to 
be reviewed at discharge” written below the sticker. Additional 
pages in the COAST CRF will be available to report key clinical, 
laboratory or AEs and bi-daily observations during the period prior 
to discharge.
Following on-site monitoring, data will be entered onto a web- 
enabled trial database directly at the site. The site will retain 
the original paper CRFs. All clinical and laboratory data will 
be recorded in the CRF and stored with a unique trial number 
identifier. All data will be regularly backed up and backup copies 
will be stored securely both on and off site.
Data will be checked and undergo validation checks for com-
pleteness, accuracy and consistency of data. Data queries that 
arise from these checks will be sent from KCTF to the trial site 
coordinators. The trial site coordinator is required to ensure that 
queries are resolved as soon as possible, including updating 
the relevant paper CRFs and the trial database as required. The 
KCTF will send reminders for any overdue data or outstanding 
queries. Following validation, data will be remotely extracted by 
ICNARC CTU once a month to generate progress reports for 
each site.
Ongoing data entry and validation and adherence to the trial 
protocol at sites will be closely monitored by KCTF; any concerns 
will be raised with the site PI.
9.1 Sample storage
All samples for storage (including those taken during hospital 
stay and those taken for research purposes, if consented to) will 
require no more than 10 ml of venous blood (varies by age). Any 
blood taken for research purposes under emergency deferred 
consent from children whose parents subsequently refuse consent 
will be confidentially destroyed.
10. Safety monitoring
10.1 Definitions
The following definitions have been adapted from Direc-
tive 2001/20/EC of the European Parliament (Clinical Trials 
Directive)72 and ICH-GCP guidelines (E6(R1), 1996).
Adverse event (AE) – Any untoward medical occurrence or effect 
in a patient participating in a trial, which does not necessarily 
have a causal relationship with the trial treatment. An AE can 
therefore be any unfavourable symptom or disease temporally 
associated with the use of the trial treatment, whether or not it is 
related to the allocated trial treatment.
Serious adverse event (SAE) – An AE is defined as serious if it:
•     results in death;
•     is life-threatening;
•     requires inpatient hospitalisation or prolongation of 
existing hospitalisation;
•     results in persistent or significant disability/incapacity; or
•     is a congenital anomaly/birth defect.
Medical judgement should be exercised in deciding whether 
an SAE is serious in other situations. Important SAEs that are 
not immediately life-threatening, do not result in death or hospi-
talisation, but may jeopardise the subject or require intervention 
to prevent one or any of the other outcomes listed in the definition 
above should also be considered as serious.
Life threatening in the definition of an SAE refers to an event in 
which the subject was at risk of death at the time of the event. It 
does not refer to an event that hypothetically might have caused 
death if it were more severe.
Unexpected and related serious adverse event - A suspected AE 
related to the treatment that is both unexpected (i.e. not consist-
ent with the expected outcomes of the treatment being offered) and 
serious.
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N.B. Suspected Unexpected Serious Adverse Reaction will not be 
assessed in this trial as it falls outside the scope of the European 
Union Clinical Trial Directive.
10.2 Severity
The assessment of severity will be graded based on the PI’s 
or a delegated local investigator’s clinical judgement using the 
following definitions:
•    None: indicates no event or complication.
•    Mild: complication results in only temporary harm and does 
not require clinical treatment.
•    Moderate: complication requires clinical treatment but 
does not result in significant prolongation of hospital stay. 
Does not usually result in permanent harm and where 
this does occur the harm does not cause functional 
limitation to the participant.
•    Severe: complication requires clinical treatment and 
results in significant prolongation of hospital stay and/or 
permanent functional limitation.
•    Life threatening: complication may lead to death.
•    Fatal: indicates that the participant died as a direct result 
of the complication/AE.
10.3 Relatedness
The PI or designee should use clinical judgement to determine 
the relationship between the trial treatment and the occurrence 
of each AE using the following definitions:
•    None: there is no evidence of any relationship to the 
trial treatment.
•    Unlikely: there is little evidence to suggest a relationship 
to the trial treatment, and there is another reasonable 
explanation of the event.
•    Possibly: there is some evidence to suggest a relationship 
to the trial treatment, although the influence of other factors 
may have contributed to the event.
•    Probably: there is probable evidence to suggest a 
relationship to the trial treatment, and the influence of other 
factors is unlikely.
•    Definitely: there is clear evidence to suggest a relation-
ship to the trial treatment, and other possible contributing 
factors can be ruled out.
10.4 Expectedness
The PI or designee must assess the expectedness for each SAE 
regardless of its relationship to the trial procedures.
•     Expected: the event is listed as an expected AE (see 
below)
•     Unexpected: the event is not listed as an expected AE 
below.
Expected AEs that could be observed in participants up to 28 days 
following randomisation:
•   Nasal trauma
•   Facial trauma
•   Pneumothorax
•   Subcutaneous emphysema
•   Aspiration
Note that this list is not extensive, other AE should be reported as 
described in Section 10.6.
10.5 Exempt adverse events
All patients eligible for COAST are critically ill and due to the 
complexity of their condition are at increased risk of experiencing 
AEs. Many of these events are expected as a result of the 
patient’s medical condition and standard treatment received in 
hospital, but may not be related to participation in the trial. 
Consequently, any unexpected AEs occurring as a result of the 
patient’s medical condition or standard hospital treatment will 
not be reported. Pre-existing conditions do not qualify as AEs 
unless they worsen, but should be documented in the patient’s 
medical notes.
10.6 Recording and reporting
All AEs that occur between randomisation and 28 days post- 
randomisation must be recorded in the patient medical notes, 
on the COAST paper CRFs and on the web-enabled trial data-
base. Information regarding date and time of event onset, severity 
and relatedness of the AE to trial treatment must be recorded.
At each clinical review the clinician or nurse will check for 
potential SAEs, grade 3 or 4 AEs and solicited AEs. SAEs will be 
reported to KCTF using an SAE form; the form should be com-
pleted, scanned and sent electronically within 24 hours of becom-
ing aware of the event. The clinician or nurse should record the 
nature of event, date of onset, severity, corrective therapies 
given, outcome, relatedness and expectedness on the SAE form, 
and the PI or designee should sign it off prior to sending. Sites 
should also report all SAEs as required by their local REC and/
or local policies. Any questions concerning AE recording and 
reporting should be directed to KCTF in the first instance via 
email or by telephone.
All SAEs must be followed-up until resolution. The PI or 
designee must provide a follow-up SAE report(s) within five days 
of the initial report if the SAE was not resolved at the time the 
initial report was submitted.
10.7 Central processing
SAEs will be reviewed immediately by a designated physician 
(SAE reviewer) in the KCTF and periodically by the ERC. 
If the event is evaluated by either the PI or the SAE reviewer 
as an unexpected and related SAE, the KCTF will submit a report 
to the appropriate ethics committees within 15 calendar days.
The KCTF will provide safety information to the ChI, TMG, 
Trial Steering Committee (TSC) and Data Monitoring Committee 
(DMC) for review on a regular basis (as deemed necessary).
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10.8 Additional monitoring and notification process
The KCTF will also monitor data for documented AEs that are 
not considered to be related to the trial treatment. In the event 
that any trial procedure does appear to be resulting in AEs, the 
ChI and/or TMG will be contacted for their opinion. If it is 
declared necessary to review the conduct of the trial, the KCTF 
will inform the appropriate ethics committees as necessary.
11. Trial monitoring and oversight
11.1 Site
This trial will be monitored according to a Monitoring and 
Quality Management Plan, which will set out the frequency of 
visits, the degree of source document verification against the 
CRFs and the requirements for triggered on-site monitoring vis-
its. Monitoring will start with 100% source document verifica-
tion, then will be reviewed for each site once a satisfactory and 
sustained performance in quality assurance is established. All 
monitoring will adhere to the ICH-GCP guidelines (E6(R1), 
1996).
A detailed site initiation visit (SIV) will be performed at each 
site by staff from KCTF. The SIV will include training in the trial 
procedures, such as delivering the trial treatments, reporting 
guidelines for AEs and data collection and management. All 
staff at sites involved in the trial will receive formal training in 
GCP through a dedicated training programme during the SIV and 
through an on-line course.
Local monitoring teams, responsible to KCTF, will oversee 
the standards and quality of the trial at each site. All monitors 
will be appropriately qualified and trained.
At each monitoring visit, monitors will:
•   verify completeness of Investigator Site File;
•   assess for any non-adherence to protocol;
•   review eligibility verification and consent procedures;
•   look for missed AE recording/reporting;
•    verify completeness, consistency and accuracy of data being 
entered on CRFs; and
•   provide additional training as needed.
The monitors will require access to all patient medical 
records, including, but not limited to, laboratory test results and 
prescriptions. The PI or delegated local investigator should work 
with the monitor to ensure that any problems detected are 
resolved.
11.2 Site trial management team
Each site will have a PI, who will have overall responsibility for 
the day-to-day management of the trial, and will employ a clinical 
team to coordinate triage and identification of eligible participants 
and administration of trial interventions. Additional clinical nurses 
will be responsible for clinical reviews and follow-up. A clinical 
nurse coordinator will manage the trial team and integrate the trial 
within routine clinical services and patient care.
Trial site coordinators are responsible for ensuring complete-
ness of trial documents, SAE reporting and interactions with 
monitors and KCTF. Support will be provided for laboratory staff 
and ward assistants to facilitate blood tests, sample preparation 
and storage. At each site, dedicated COAST administrators will 
manage trial operations and human resource issues.
Overall trial management, training and monitoring and data 
management will be coordinated from the KCTF, based in 
Kenya. The ICNARC CTU, based in London, will oversee trial 
management by teleconferences and face-to-face meetings with the 
TMG.
11.3 Trial management group
The TMG will be comprised of the ChI, site PIs and 
co-investigators. The TMG will meet approximately once a year 
in-person and will hold regular monthly teleconferences to discuss 
general trial matters. In addition, the site PIs will summarise their 
progress and discuss any challenges and difficulties at their site. 
All decisions regarding the overall running of the trial will be 
made in this forum, with the exception of matters of fundamental 
importance to the viability of the trial or that require major 
changes to the protocol – these will be referred to the TSC.
11.4 Trial steering committee
The progress of the trial will be monitored and supervised by 
the TSC. It will meet approximately once a year. The TSC will 
compose of an independent chair (Professor Elizabeth Molyneux, 
OBE former Head of Paediatrics Queen Elizabeth Hospital, 
Blantyre; Founder of ETAT; and member of a number of WHO 
guideline committees) and a majority (60%) of independent 
members (composed in experts in international child health 
and intensive care). Non-independent members will include the 
ChI and representatives from the co-investigators and from each 
participating country. Representatives from the Funder and 
Sponsor will be invited to the meetings as observers.
11.5 Data monitoring committee
An independent DMC will be set up to review data on enrol-
ment, safety, adherence to the trial protocol and efficacy at regular 
intervals and in strict confidence. It will meet approximately 
once a year. The DMC will report to the TSC and to the Ethics 
Committee in each country, if, in their view, the data provide 
proof beyond reasonable doubt that one of the allocated strategies 
is better than its comparator in terms of the primary outcome. 
The TSC will then decide whether to amend (which may include 
removing one of the intervention arms) or stop the trial before 
the end of the planned follow-up. The DMC will be comprised 
of a chair, Professor Timothy Peto, a statistician and three 
other independent members (see Supplementary File 4: DMC 
Charter).
11.6 Endpoint review committee
An ERC will be set up to review clinical data and will determine 
the validity of the endpoints. The ERC will adjudicate endpoints 
blinded to randomised allocations; relationship to all possible 
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trial treatments (liberal oxygenation, permissive hypoxaemia and 
high and low flow oxygen delivery) will be solicited to avoid 
unblinding. The ERC will be made up of an independent chair 
(Dr Jennifer Evans) and will include the PIs from each site 
as well as other independent clinicians.
12. Trial closure
12.1 End of trial
The end of the trial will be when the final participant has com-
pleted their 28-day follow-up (or 90-day follow-up if applicable). 
The Declaration of End of Trial Form will then be submitted to the 
relevant ethics committee(s), as required.
12.2 Archiving
At the end of the trial, the KCTF will securely archive all central 
and site essential trial-related documentation and samples 
taken for a minimum of 10 years, in line with Medical Research 
Council (MRC) guidance on Good Research Practice73, and 
thereafter confidentially destroyed. All archived documents must 
be available for inspection and monitoring by appropriate 
authorities upon request.
12.3 Early discontinuation
Should a site choose to close to participant recruitment before 
the end of the trial, the PI must inform the KCTF in writing. 
Follow-up, as per the trial protocol, must continue for all par-
ticipants already recruited into the trial at that site. Sites that 
contravene the trial protocol and the Site Agreement will be 
subject to review by the TMG and Sponsor.
The trial may be stopped early by the TSC. In which case, sites 
will be informed in writing by the KCTF of the reasons for early 
closure and the actions to be taken as regards the treatment of 
participants. All randomised participants will continue to be 
followed up as per the trial protocol.
13. Statistics
A Trial Statistician will be based at ICNARC CTU, under the 
supervision of Dr David Harrison (Senior Statistician, ICNARC 
CTU), and will provide statistical support for DMC analyses.
13.1 Sample size calculation
Sample size calculations were informed by identifying patients 
meeting the proposed COAST inclusion criteria within two 
datasets: the FEAST trial (n=873/3170; 28%); and the Kilifi  
Hospital, Kenya admission cohort (n=2609/36,621; 7%). Based 
on these data, it was estimated that two thirds of eligible children 
would present with SpO2 ≥80% (FEAST 63%; Kilifi 69%). Base-
line 48-hour mortality for children receiving low flow oxygen 
was assumed to be 9% for children with SpO2 ≥80% (FEAST 
10%; Kilifi 9%) and 26% with SpO2<80% (FEAST 30%; Kilifi 
26%). Due to the complex nature of the design, power calcula-
tions were undertaken by simulating datasets under the assumed 
alternative hypotheses and calculating the proportion of simu-
lated datasets in which a significant effect (P<0.05) was detected 
for each of the two comparisons74. Based on these simulations, 
a total sample size of 4,200 children would give 90% power to 
detect a clinically relevant difference of a 33% RR reduction 
associated with liberal oxygenation compared with permissive 
hypoxaemia, and a clinically relevant difference of a 25% RR 
reduction for high flow compared with low flow oxygen delivery.
The sample size calculation is based on the primary outcome 
of mortality at 48 hours with no losses to follow-up expected. 
Losses to follow-up are anticipated to increase to 2% at 28 days 
post-randomisation, based on data from the FEAST trial24.
13.2 Analysis plan
The analyses will be described in detail in a full Statistical Analysis 
Plan. This section summarises the main issues.
All analyses will be undertaken using the intention-to-treat 
principle with a two-sided P-value of P<0.05 taken to indicate 
statistical significance.
The primary outcome (48-hour mortality) will be analysed as a 
binary outcome using logistic regression including both treatment 
allocation variables simultaneously and adjusted for the stratifying 
factors (baseline SpO2 and trial site).
Secondary outcomes will be analysed using generalised linear 
models, with the same model structure as for the primary outcome 
above, as follows:
•    Treatment failure at 48 hours, re-admission to hospital 
by 28 days, neurocognitive sequelae at 28 days and 
disability-free survival to 28 days will be analysed as 
binary outcomes using logistic regression, with all deaths 
included in the failure group.
•    Time to hypoxaemia resolution will be analysed as a 
time-to-event outcome using a Fine and Gray competing 
risks model to account for the competing risk of mortality.
•    Length of initial hospital stay, days alive and free from 
receipt of oxygen and anthropometric status will be 
analysed as continuous outcomes using linear regression.
•    Survival to 28 days will be analysed as a time-to-event 
outcome using a Cox proportional hazards model.
•    Resolution of neurocognitive sequelae at 90 days will be 
analysed as a binary outcome using logistic regression, only 
among those with neurocognitive sequelae at 28 days.
Pre-specified subgroup analyses will assess whether the effects 
of the two interventions vary according to categories of baseline 
SpO2 (<80%, 80–84.9%, 85–89.9%, 90–91.9%) and by trial site. 
Additional hypothesis-generating analyses will investigate whether 
there is any evidence for a different impact of the interventions 
according to the following categorical variables: fever; malaria; 
microbiological evidence of sepsis (blood culture or retrospective 
molecular diagnosis); radiographic evidence of pneumonia; HIV; 
severe anaemia (haemoglobin <5g/dl); and undiagnosed sickle 
cell disease. Subgroup analyses will be conducted by testing the 
significance of interaction terms in the regression models as 
specified above.
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13.3 Interim analysis
The DMC will meet to review unblinded data for at least 525, 1575 
and 2625 participants (corresponding to 3 months, 9 months and 
15 months at the anticipated recruitment rate). Guidelines to 
recommend early termination will be based on a Peto-Haybittle 
stopping rule (P<0.001). A recommendation to discontinue 
recruitment, in all participants or in selected subgroups, will be 
made only if the results are likely to convince the general clinical 
community and participants in COAST.
14. Ancillary studies
14.1 Economic and cost-effectiveness evaluation
The cost-effectiveness of oxygen delivery strategies will be esti-
mated by comparing clinical outcomes and costs for participants 
receiving each of the trial treatments. Resource utilisation data 
and unit cost data (e.g. basic costs, literature and other health- 
economic data) will be collected as part of the trial dataset and 
also collated based on datasets collected in other trials of acutely 
sick children.
14.2 Molecular diagnostics
Two molecular methods are being used increasingly in research 
and clinical practice to identify bacteria. 16S ribosomal deoxyri-
bonucleic acid (16S rDNA), common to all species of bacteria, 
can be detected with a broad-range polymerase chain reaction 
(PCR); specific quantitative PCR (qPCR) can also be used to 
quantify the 16S rDNA subunit to measure directly the number 
of bacteria. However broad range 16S rDNA PCR is subject to 
artefact from endogenous and exogenous bacterial products75–77 
and therefore without either sequencing the PCR product, or car-
rying out more sensitive qPCR, there is concern that changes in 
the qPCR may not be due to circulating organisms. Unfortu-
nately, sequencing the 16S rDNA has so far yielded results com-
patible with environmental contamination rather than recognised 
gut commensals. The use of specific primers renders qPCR less 
vulnerable to background contaminants than broad-range 16S 
rDNA PCR, and therefore more sensitive78,79. The disadvantage 
of qPCR is the need to predict which bacterial species are likely 
to be relevant.
The goal of this study would be to identify the role of bacteria 
in the aetiology of lethal pneumonia in African children. Pre-
vious studies have shown comparable results between frozen 
EDTA plasma and whole blood, and so we would assay standard 
16S rDNA PCR, and a panel of 10 qPCR reactions (including 
Enterobacteriaceae, a panel of anaerobes, Streptococcus pneumo-
niae, Staphylococcus aureus, group A streptococcus).
White and red cell pellets collected into a 2ml EDTA bottle 
taken at enrolment, (stored at -80°C) and plasma will be stored and 
shipped at the conclusion of the study to Kilifi, Kenya and molecu-
lar diagnostics will compare the range of pathogens identified in 
cases (deaths) and controls (survivors) frequency matched by 
age group, study site and season.
14.3 Investigation of respiratory viruses
Respiratory viruses (RVs) are a major cause of acute lower res-
piratory tract infections worldwide80. However, in developing 
countries the potential role of RVs in life-threatening disease and 
mortality remains uncertain, e.g. influenza81. The present trial, 
in which samples will be collected from children with a high 
mortality risk, provides an important opportunity to elucidate this 
role. Furthermore, data are scarce on the occurrence of RVs in 
paediatric pneumonia cases in Uganda or Kenya, and almost 
nothing is known for Central and Eastern Africa on the origins 
and spread of these viruses. Nasal pharyngeal/oro-pharyngeal 
swabs samples will be stored and batched transferred to Professor 
Nokes viral pathogen laboratory in Kilifi, Kenya. Ribonucleic 
acid (RNA) extracted from NP/OP swabs will be screened for a 
broad range of RVs, including influenza viruses, Respiratory 
Syncytial Virus (RSV), coronaviruses and rhinoviruses using a 
multiplex real time PCR assay system82. Partial and/or whole 
genome sequencing of the virus positive samples, for example 
RSV83, and influenza84, amongst other respiratory targets will be 
undertaken.
The outcomes of this study will be:
(i)    the prevalence and seasonal patterns of a range of respira-
tory viruses in children with life threatening features of 
respiratory disease;
(ii)    estimates of the risk of death in RV positive relative to 
negative children; and
(ii)    information on the sources of viruses and patterns of 
spread in East Africa.
14.4 Short period incidence study of severe acute 
respiratory infection (sprint-sari)
SPRINT-SARI is a global multi-network, multicentre, prospec-
tive, short period incidence observational study of all severe 
SARI patients admitted to the in-patient unit of interest (ICU or 
hospital ward), during a defined 5-or 7-day study period once annu-
ally. The Chief investigator is Professor Steven Webb, Clinical 
Professor, University of Western Australia, Royal Perth Hospital. 
The primary aim of this study is to establish a research response 
capability for future epidemics / pandemics through a global 
SARI observational study. The secondary aim of this study is to 
describe the clinical epidemiology and microbiology profiles of 
patients with SARI. Since children with severe pneumonia will 
be enrolled across 5 sites (2 countries) in COAST, this will act 
as an opportunity to provide data to this global platform. Only 
basic clinical and some diagnostic data will be provided from 
each site together with outcome data. There will be no linking of 
the data to the trial intervention and only fully anonymised and 
de-identified data will be submitted to the centrally coordinated 
database for SPRINT-SARI.
14.5 Sickle cell disease status
The mortality rate for children with sickle cell disease (SCD) 
admitted to hospital with triage features, fulfilling severe and 
very severe pneumonia, is three-fold high compared to children 
without SCD (Professor Thomas N. Williams, unpublished). 
The reasons for high mortality in this group remains unclear and 
whether this may indicate a diagnosis of ‘chest syndrome’ or a 
much higher risk of bacterial infection including gram negative 
organisms. As sickle cell status is likely to influence the outcome 
in this study, we aim to test all children for this common condition 
in Africa (with SCD and sickle cell trait being present in 2% and 
7% of children with SP and VSP).
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White and red cell pellets collected into a 2ml EDTA bottle (see 
section 14.2) will be stored at -80°C and shipped at the conclu-
sion of the study to Professor Williams haemoglobinopathy labora-
tory (Kilifi, Kenya). We will extract a sample of DNA from this 
sample from study participants to describe the distribution of 
HbSS using PCR. Patients found to be positive for HbSS will 
be recalled for counselling and for confirmatory testing and if 
confirmed to be suffering from HbSS they will be encouraged to 
attend the outpatient clinic for regular treatment.
15. Ethical compliance
15.1 Trial registration
This trial has been registered with the ISRCTN Registry 
(ISRCTN15622505).
15.2 Central ethical compliance
Favourable ethics opinion has been obtained from the Impe-
rial College REC. This trial has been submitted and received 
approval by the relevant RECs/Institutional Review Boards and 
by required regulatory authorities in all participating countries.
The trial will be conducted in accordance with the recommen-
dations for research on human subjects in the Declaration of 
Helsinki85, the ICH-GCP guidelines (E6(R1), 1996) and the 
applicable national regulations.
15.3 Local ethical compliance
It is the responsibility of the PI to obtain the necessary local 
approvals and provide them to the KCTF prior to site activation.
COAST will only be conducted at sites where all necessary 
local approvals for the trial have been obtained and a Site 
Agreement between the Hospital (site) and the Imperial College 
London (Sponsor) has been signed.
15.4 Confidentiality and data protection
Participants’ identification data will be collected as part of the 
trial follow-up procedures. The KCTF and the ICNARC CTU 
will preserve the confidentiality of participants taking part, which 
will comply with requirements for data protection in the 
countries where the research is being conducted. All data will be 
anonymised prior to presentation or publication of any results.
15.5 Patient, carer and public involvement and 
engagement
Each site would either use their existing Community Advi-
sory Board (CAB) or form a specific patient liaison group to 
feedback concerns and questions from the community and hear 
about the latest developments in the trial and the wider scientific 
community, where possible.
Each of the country PIs have discussed the trial with their local 
hospital CABs (if in existence) and informed Ministry of Health 
about the trial. Dialogue with these groups will be maintained 
through regular briefing meetings during the course of the trial 
and will be a standing item at each TSC meeting in order to 
rapidly facilitate dissemination and implementation of results. 
Policy briefs and presentations at national meetings will be used to 
disseminate results to policy makers.
15.6 Declaration of interests
All trial investigators have confirmed that they do not have 
any financial or other conflicts of interest to declare in relation 
to this trial.
16. Sponsorship and funding
16.1 Sponsorship
Imperial College London will act as Sponsor for this trial and 
delegate the responsibility of overseeing the implementation of 
the trial to KCTF and the ICNARC CTU. Imperial College 
London holds negligent harm and non-negligent harm insurance 
policies, which apply to this trial.
16.2 Funding
The trial is supported by grant funding from the UK MRC, the 
UK Department for International Development (DFID) and the 
Wellcome Trust through the Joint Global Health Trials scheme. 
The trial is also supported by Fisher & Paykel Healthcare, who is 
providing equipment and technical support.
A written agreement with the site PI and/or the PI’s institution 
and Imperial College London will outline the funding arrange-
ments to sites. The TSC will meet and review the financial aspects 
of the trial at least annually and report to the Sponsor.
17. Dissemination policy
All publications and presentations relating to the trial will be 
authorised by the TMG. The first publication of the trial results 
will be in the name of the TMG, if this does not conflict with the 
journal’s policy. If there are named authors, these will include the 
ChI, Trial Statistician and Trial Manager. Members of the TMG, 
TSC and DMC and other contributors will be cited by name, 
if this does not conflict with the journal’s policy. Authorship of 
sub studies initiated outside of the TMG will be according to 
the individuals involved in the project but must acknowledge the 
contribution of the TMG and KCTF.
The TSC is the custodian of the data and specimens generated 
from the trial; trial data are not the property of individual 
participating investigators or health care facilities where the data 
were generated.
During the course and following completion of the trial there will 
be publications, including manuscripts and abstracts for pres-
entations at national and international meetings, as well as the 
preparation of manuscripts for peer-reviewed publication. 
In order to avoid disputes regarding authorship, a consen-
sus approach will be established that will provide a framework 
for all publications derived in full or in part from this trial. 
Authorship criteria will be determined using the guidelines 
provided by The International Committee of Medical Journal 
Editors. The following approach is derived from the Lancet and 
from the publication policies used in other MRC clinical trials:
•    All publications are to be approved by the TMG and TSC 
before submission for publication. Any publication arising 
before the end of the trial will also be approved by the DMC 
in order to ensure that the primary objective of the trial is not 
compromised. In particular, no analyses by randomised group 
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of any outcome (primary, secondary or other) in either the main 
trial or associated sub studies will be conducted or presented 
before the end of the trial, other than those for interim review 
by the DMC. The TMG and TSC will resolve problems of 
authorship and maintain the quality of publications.
•    Manuscripts arising from the trial will, wherever possible, 
be submitted to peer-reviewed journals that enable Open 
Access via UK PubMed Central within six months of the 
official date of final publication. All conference presenta-
tions will be made available as soon as possible after the event 
via the COAST website. All publications will acknowledge 
the trial's funding sources.
•    For all publications, the TMG will nominate a chairperson or 
approve an individual’s request to chair a manuscript writing 
committee. The chair will usually be the primary or senior 
author. The chairperson is responsible for identifying fellow 
authors and for determining the order of authorship that will 
appear on the manuscript. The TSC will resolve any problems 
of authorship and maintain the quality of publications.
•    The TMG will maintain a list of investigators to be presented 
in the acknowledgements at the end of the paper. This list 
will include investigators who contributed to the investigation 
being reported but who are not members of the writing 
committee. In principle, sub study reports should include all 
investigators for the main trial, although in some instances, 
where a smaller number of investigators have made any form of 
contribution, it may be appropriate to abbreviate the listing.
•    All headline authors in any publication arising from the main 
trial or sub studies must have a made a significant academic 
or project management contribution to the work that is being 
presented. “Significant” must be defined by a written 
declaration of exactly what the contribution of any indi-
vidual is believed to have been. In addition to fulfilling the 
criteria based on contribution, additional features that will be 
considered in selecting an authorship group will include the 
recruitment of participants who contributed data to any set of 
analyses contained in the manuscript, the conduct of analyses 
(laboratory and statistical) and leadership and coordination of 
the project in the absence of a clear academic contribution.
•    The data derived from this trial are considered the property of 
the TSC. The presentation or publication of any data collected 
by the participating investigators on participants recruited into 
this trial is under the direct control of the TMG and TSC (and 
the DMC before the end of the trial). This is true whether the 
publication or presentation is concerned directly with the 
results of the trial or is associated with the trial in some other 
way. However, although individual participating investigators 
will not have any inherent right to perform analyses or 
interpretations, to make public presentations or seek publi-
cation of any of the data other than under the auspices of and 
with the approval of the TMG and TSC (and the DMC before 
the end of the trial), they will be encouraged to develop sub 
studies or propose analyses subject to the approval by the 
TMG and TSC (and the DMC before the end of the trial). 
Any requests for access to raw data will be welcomed as long 
as they are scientifically valid and do not conflict with the 
integrity of the trial or ongoing analyses by the trial team.
Outcome data by randomised group will not be revealed to the 
participating investigators until the data collection phase and 
primary full analysis of the trial has been completed. This 
policy safeguards against possible bias affecting the data 
collection. The DMC will monitor the outcome results and may 
recommend that the trial be stopped for safety reasons or if 
a definitive answer is reached earlier than the scheduled end of 
the trial.
18. Discussion
Systematic and policy reviews have indicated the need for formal 
evaluation of the hypoxaemia threshold for which oxygen should 
be targeted and how best to administer oxygen; thus COAST was 
designed in response. The trial is pragmatic, enrolling children pre-
senting with respiratory symptoms and hypoxaemia, and thus will 
include large subgroups of children with pneumonia, malaria and 
other critical illness. This will ensure that the results are applicable 
to health services in Africa that typically have little or no access 
to specialist respiratory support facilities. The trial was designed 
to address the poor outcomes of children in sub-Saharan Africa, 
which are associated with high rates of in-hospital mortality, 
9–10% (for those with oxygen saturations between 80% and 
92%) and 26–30% case fatality for those with oxygen satura-
tions <80%, indicating that the current recommendations and/or 
management strategies are not working in practice. COAST trial 
will target children, but not newborns, as this group require a 
separate trial designed to address a different set of objectives and 
interventions. The COAST trial aims to provide the relevant evi-
dence for policy makers and health services by evaluating key 
elements of an integrated management strategy in African hos-
pitals on the basis of clinical effectiveness and costs. The health 
economics component is vital to ensuring that we provide 
evidence not just on effectiveness, but also cost-effectiveness, 
to allow policymakers to make decisions on how best to 
allocate scarce health resources.
19. Trial status
The trial started enrolment in February 2017 and to date (17th 
December 2017) has enrolled 907 participants, with one interim 
analysis by the DMC. The trial will contribute new knowledge to 
the relevant academic disciplines, including opportunities for 
additional sub-studies to increase our knowledge and understand-
ing of host response to oxygenation strategies.
Protocol versions
Date Amendment 
no.
Protocol 
Title
Changes
25th January 
2016
1.0
7th July 2016 1st 2.0 Relocation of trial 
site from Kinshasa to 
Mombasa
11th January 
2017
2nd 2.1 Minor amendments and 
clarifications 
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Click here to access the data.
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 study protocols that a readers requires. There appear to be no deficits in how the study has been outlined.
One comment is that throughout the article the terms hypoxia and hypoxaemia have been used
interchangeably. Hypoxia refers to a lack of oxygen at a cellular level. This, however, is a study of patients
with hypoxaemia, a lack of oxygen in the blood. The term hypoxaemia should be used throughout, unless
the authors are specifically referring to a cellular oxygen deficit. 
There are one or two minor typographical errors in the manuscript. 
I see absolutely no reason why this article should not be indexed and wish the investigators the very best
of luck with this exciting piece of research. 
Is the rationale for, and objectives of, the study clearly described?
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Is the study design appropriate for the research question?
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Are sufficient details of the methods provided to allow replication by others?
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Are the datasets clearly presented in a useable and accessible format?
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 doi:10.21956/wellcomeopenres.13812.r26893
   Steve Cunningham
Department of Child Life and Health, University of Edinburgh, Edinburgh, UK
This is a well presented and detailed study protocol of a pivotal trial. The data underpinning the trial are
considerable. The trial should significant enrich the quality of data for the management of hypoxaemic
LRTI for children in developing healthcare settings.
 
As a de novo reader of the protocol I have the following comments:
 
Study Rationale:
 
Justification for oxygen saturation target of ≤92%.
Current WHO standard is a 90% oxygen saturation target. In applying a 92% target for oxygen
supplementation the group directly challenge what is current practice in developing healthcare.
Justification for this change is very limited within the protocol report; whilst 92% is current practice in a
number of developed healthcare settings, it is without trial evidence (with some evidence as quoted that a
90% target has been trialled successfully in those under 12 months of age with bronchiolitis). There are
two effects of this that it would be helpful to address within the protocol introduction (1) Maintaining
supplemental oxygen above 90% is a significant healthcare resource (we estimated the difference in
hospital stay to be 22 hours for a 94% rather than 90% target, so possible c10 hours per patient for 92%)
(2) Recruitment to COAST B will be skewed to those with a higher baseline SpO , by the distribution of
SpO  in acute respiratory disease; it might be estimated that 40% of all COAST B participants will arrive
with a baseline SpO2 in the 90-92% range (Hooli 2016).  It would be very helpful if the protocol could
discuss this probable skewed recruitment pattern to COAST B, in the context of the ability of the study to
provide helpful data within an 81-89% SpO  to enable a conclusion to be drawn incorporating current
WHO guidelines. The number of children with SpO  at baseline 90-91% who died in figures 3 and 4 are
few and so the justification is important.
 
Justification for limiting one arm of the study (high flow oxygen) to 48 hours regardless of clinical status at
that time.
In practice, from a clinical perspective this would be difficult to justify and it is most likely that high flow
devices would not be withdrawn from children who continued to be critically ill at 48 hours. Please provide
justification and method of assessment for how this might this influence outcomes post 48 hours in those
who had high flow removed?
 
Overemphasis on ‘equipoise’ for harms of supplemental oxygen
The introduction provides significant weight to the potential harms of supplemental oxygen. The studies
generally quoted consider extremely high concentration oxygen (>90%), something that will not be
achieved within either study arm. There is no evidence of harm from low or high flow oxygen delivery
systems, whilst there is clinical trial and pathophysiological theory for benefit. The introduction should be
more balanced in this assessment. Whilst it is appropriate to consider potential adverse effects of an
intervention (supplemental oxygen), this could not be considered equipoise for this intervention.
 
 
Study Design
 
 
Details of standard care
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Details of standard care
What is the standard of care for children with lower respiratory tract infection and low oxygen saturation in
the hospitals taking part? Is supplemental oxygen by nasal cannula/mask etc a standard of care. If so it
would be helpful to state this. In the hospitals taking part, does standard of care include an ability to
provide high flow oxygen, CPAP or intensive care.
 
Data management appears appropriate. I would not consider myself appropriately qualified to comment
on the statistical methodology.  
 
Methodology details
 
Detail of interventions
It would be helped if the interventions could be more clearly outlined, i.e. what have local clinicians been
told to apply, how and when. What is low flow oxygen, ?1 or 2 litres per minute of nasal cannula oxygen
?6 litres by mask, what is the maximum flow to be applied? How is the AIRVO2 high flow oxygen applied,
how many litres per minute of flow and to what oxygen concentration. Is there a titration policy for starting,
increasing and weaning oxygen supplementation and flow? Are clinicians responsive to SpO
measurements. Is it possible within the trial for crossover, i.e. if at 30 hours SpO  in permissive arm is
78% what would happen, if a child on low flow oxygen were deteriorating at 16 hours could they be
transferred to high flow or to a CPAP device where available?
 
10.5 Who will decide whether unexpected AEs are a result of the patients medical condition or standard
hospital treatment. How will this be standardised across sites?
 
11.6 Endpoint review committee. To whom will they report and with what frequency?
 
The datasets are clear
 
Additional point: Interchangeable use of the words hypoxia and hypoxaemia should be corrected. In
almost all instances the word hypoxaemia is appropriate, i.e. low blood oxygen, as opposed to hypoxia
which is critically low oxygen at tissue level. The challenge in healthcare is to understand what lower limits
of hypoxaemia may be reliably tolerated without placing patients at risk of hypoxia and consequent
hypoxic injury.
Is the rationale for, and objectives of, the study clearly described?
Partly
Is the study design appropriate for the research question?
Partly
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Yes
 No competing interests were disclosed.Competing Interests:
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 I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Author Response 15 Nov 2017
, KEMRI-Wellcome Trust Research Programme, KenyaKathryn Maitland
We thank Dr Cunningham for his very careful and thoughtful review. Before we address some of
the concerns he raised we believe it is worthwhile to summarise the context of pneumonia
management in most African hospitals.
 
Firstly, the burden of disease is substantial, with few hospitals able to sustainably deliver oxygen to
most children requiring oxygen (Page 3). As oxygen cylinders are expensive to maintain (and
frequently faulty) as the source of oxygen, the WHO’s preferred option is oxygen concentrators.
The WHO conducted a survey of 231 health facilities in 12 African countries between 2007 and
2009. Only 44% reported uninterrupted oxygen supplies, 24% possessed a functioning oxygen
concentrator and 35% had reliable power (Belle et al 2010; Page 5). Furthermore, most hospitals
do not use pulse oximetry to target oxygen therapy, relying on clinical signs of pneumonia – which
are very non-specific and thus only identify few children with hypoxaemia (Page 4). Thus, usual
care is poorly targeted oxygen therapy with unreliable supplies of oxygen. The vast majority of
hospitals have no access to intensive care outside of private health facilities and very few have
access to CPAP or high flow/AirVO  (these are largely donor driven). This includes the hospitals
involved in the COAST trial.
 
A WHO ‘Evidence for technical update of pocket book recommendations’ was conducted in 2012
and recommended that oxygen therapy should be given to all children with signs of severe
pneumonia or hypoxaemia (oxygen saturations < 90%) rated as a Strong recommendation, very
(Pages 5-6).  The technical advisory group identified the following researchlow quality evidence 
gaps: ‘clinical studies comparing outcomes when oxygen is given at different thresholds’ and
‘large-scale effectiveness trials of improved oxygen systems on outcomes from pneumonia’. The
COAST trial was designed to directly address these questions in children in Africa, including
consideration of both lower and higher thresholds than the current recommendation.
 
With regard to the balance between presenting the potential benefits and harms of oxygen therapy,
there are no relevant studies/trials to support the current recommendation and ‘oxygen toxicity’ is a
relatively novel concept in Africa – and required substantial justification (on request during ethics
review). We do not believe that we have provided an imbalanced case for the need for a trial.  A
substantial section of the introduction provides substantial evidence of poor implementation and
challenges faced by health services. However, even if these challenges were addressed with
oxygen systems being prioritised there remains a scientific question about the role of oxygen as a
life-saving drug. The data provided from the FEAST trial (control arm) and KEMRI Wellcome Trust
Programme Kilifi Admission Cohort (all unselected admissions) who were all had access to oxygen
and routine medications to treat underlying infections (provided by external funding) provided the
data on which our sample size was calculated. These underpinned the need for a trial – even in
context of a clinical trial (with very close monitoring), outcome in children with hypoxaemia was
unsatisfactory (Pages 7-9).    
 
Selecting a higher threshold for investigation (<92% rather than <90%) enables the trial to
investigate whether, if oxygen therapy is beneficial, the WHO threshold should be revised to
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 investigate whether, if oxygen therapy is beneficial, the WHO threshold should be revised to
include targeting a higher threshold (which is compatible with international recommendations).
Logically, following on from this argument, if we had targeted < 90% and the COAST trial confirms
that oxygen is life-saving then a future trial to examine whether it should be targeted to children
with saturations 90-91% would require a massive trial, with little hope of securing funding. The
COAST trial includes a health economic evaluation (from a health services perspective) so we will
be able to provide future policy makers with data on both the clinical and cost-effectiveness of
alternative oxygen strategies, taking into account baseline oxygen saturation.
 
Dr Cunningham questions limiting high flow/AirVO  therapy to 48 hours (the primary endpoint). All
children irrespective of arm after 48 hours will continue with use of low flow oxygen if needed. The
48-hour endpoint was selected since it captures ~ 85% of the mortality of the COAST participants
and therefore strategies to improve outcome should focus on the high risk period; where the
majority of impact of a life-saving therapy is likely to occur. Currently, the standard of care is not to
give high flow/AirVO  therapy and, pragmatically, using high flow/AirVO  over days or weeks
following admission would limit the availability of the machine, and therefore the numbers that
could be recruited, with little potential for added improvement in mortality. If the COAST trial were
to show that AirVO  therapy improved outcome at 48 hours, we would also have captured
important data on the 28 day outcome of all children, which may lead to refinements in guidelines
in future implementation trials (balancing efficacy over cost-effectiveness). The latter consideration
for policy makers is extremely important in resource-limited health services.  
 
Dr Cunningham points out that the protocol does not include information about the flow rates,
oxygen/air blending titration and weaning protocols. However, these are covered in great detail in
the Manual of Operations, that ‘operationalises’ the trial protocol which the clinical teams have
been taught to follow. This is a live document that from time to time is revised to address evolving
challenges. This is a very standard method for ensuring compliance and flexibility of the
implementation of the trial – and reduces the number of times that the protocol needs to be
returned to all three ethics committees (Imperial, Kenya and Uganda) and regulatory bodies for
minor adjustments in the SOPs.
 
There is no cross-over permitted between arms. Providing oxygen to the permissive hypoxaemia
arm if saturations ever fall below 80% is part of the randomised strategy for this arm so this is not
cross-over. High flow/AirVO is the experimental therapy, by including a cross-over to this arm for
children not responding to their alternative oxygenation strategy (low flow or permissive) suggests
that we already know in the context in which the trial is being conducted that this is a superior
strategy. There are no data to support this. The COAST trial will generate these data, and the
effectiveness of high flow/AirVO  cannot be assumed until demonstrated in an adequately
powered trial.
 
All SAE reports are prepared by the clinicians and finalised by the site Principal Investigator, who
attribute causality as per a detailed SOP for SAE reporting, for which there was an extensive
training during the site initiation visit.  These are sent to the SAE reviewer in Kilifi (a clinician) and
copies sent to the national ethical review committees. The SAE reviewer is responsible for
checking completeness of the report and active dialogue with the responsible clinician/PI to ensure
all are reported according to the SAE SOP. The SAE reviewer sends unblinded copies to the DMC
for review during DMC meetings. The SAE reviewer also sends copies blinded to trial arm to the
Endpoint Review Committee (chaired by Dr Jennifer Evans) who adjudicate on the mode of death
and whether this was causally related to trial interventions. This is the method of SAE reporting we
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 and whether this was causally related to trial interventions. This is the method of SAE reporting we
used in the FEAST trial and currently in our transfusion trial (TRACT). 
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